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ABSTRACT 
 
Herpes simplex virus 1 (HSV-1) induced stromal keratitis (SK) is a potentially blinding disease 
which can result in chronic immunoinflammatory stromal keratitis (SK) lesions. These lesions 
occur as a result of immunopathology and basically involve IFN-gamma producing CD4+ T cells 
(Th1) and neutrophils. Regulatory T cells are known to play a crucial part in regulating these 
effector T cell responses and hence hold a significant value in constraining SK lesions. In 
humans, SK is usually a result of reactivation of HSV-1 from the trigeminal ganglion and the 
patients infected with this virus usually undergoes anti- viral and anti- inflammatory treatments 
which are not entirely satisfactory. Hence, new approaches to control SK are needed.  
The first part of this dissertation work, sheds light on the pathogenesis and control of SK lesions 
with emphasis on new methods to control SK. This is followed by chapter 2 in which the role of 
Interferons in viral immunity is studied with the focus on Interferon lambda (IL-28A). Here, we 
have shown that administration of IL-28A in mice after HSV-1 infection leads to reduced SK 
lesions and also that the viral load after the infection is reduced in the mice treated with IL-28A. 
The third chapter of this thesis describes the role of Retinoic acid in the treatment of SK lesions. 
We found out that retinoic acid has a prominent role in reducing SK lesions as it is known to 
stabilize Treg population and also dramatically reduce the T effector population (Th1 cell 
population). In-vitro and in-vivo experiments have been done to understand the mechanism and 
role of Retinoic acid.  
 
 v 
The fourth chapter includes another approach to control SK lesions by the use of the 
superagonist monoclonal antibody CD28SA. Treatment with this antibody showed remarkable 
results with raised Treg to Th1 ratio and increased the function of Treg resulting in the control of 
SK lesions.  
The research work shown here depicts fruitful ways of controlling SK pathogenesis which 
involves innate as well as adaptive immune response targets. The role of interferons, metabolites 
of vitamins and superagonist antibodies were studied for the first time in SK pathogenesis. 
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Herpes Simplex Infection  
Herpes Simplex Virus 1 (HSV-1) belongs to the family of herpesviridae that infects humans. The 
structure of herpes viruses comprises a large double-stranded, linear DNA genome encased 
within an icosahedral protein cage called the capsid, which is wrapped in a lipid bilayer called 
the envelope. The tegument joins the envelope to the capsid and this complete unit is known as 
the virion. Epidemiologically, almost 85-90% of the human population is infected with herpes 
infection1. Infection with herpes does not usually cause symptoms but ocular infection with 
HSV-1 can cause a destructive immunopathological disease which is herpes stromal keratitis 
(HSK)2. This virus can be lethal to patients but is rare. Most infected persons suffer lesions but 
recover without significant complications. Therefore, infection can be acute which can result in 
chronic immunoinflammatory lesions that is the most common cause of infectious blindness in 
the developed world but can be resolved if treated effectively. Generally there are two types of 
HSV-1 infection, primary and recurrent disease2. During  primary infection, the transmission of 
HSV infection occurs through contact with mucosal surfaces or abraded skin, and the 
oropharyngeal mucosa3. Following infection, replication starts in epithelial cells and after 5 to 6 
days of infection, replicating virus is usually no longer detectable in the eye  and is then followed 
by retrograde migration of the virus to the trigeminal ganglion (TG) where the virus becomes 
latent which means the virus does not replicate and is non-functional and is maintained in the 
host. SK in humans occur when the virus gets reactivated on certain conditions like that of host 
exposure to stress or immunosuppression4. Once the virus is reactivated, it usually migrates to 
the initial site of infection causing inflammatory reactions in that site5. The mechanistic details of 
its pathogenesis largely comes from studies in animal models.  
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SK Disease Pathogenesis 
SK pathogenesis is very complex in humans but it is mainly thought to be a CD4
+ 
T cell 
inflammatory reaction caused mainly by the influx of Th1 cells and accompanied by the growth 
of newly formed blood vessels which leads to angiogenesis.  Formation of blood vessels in the 
eye leads to vision impairment and hence, blindness6. To understand the pathology of SK 
lesions, most of the studies are performed on mouse models and for the reactivation events, rabit 
models are being used. In different animal models of infection, CD4
+ 
T cells mainly Th1 cells 
orchestrate SK lesions generated in the eye. Animals that lack T cells, fail to develop SK but 
lesions can be restored in such animals with adoptive transfer of CD4
+ 
T cells1. Virus infection 
triggers numerous signaling events many of which are driven by pathogen activating molecular 
pattern (PAMP) properties of the virus. These include at least 3 TLR ligands (TLR- 2, TLR-3 
and TLR-9) all of which activate the innate immune system in some way 7-8. Curiously, humans 
without TLR-3 responsiveness show markedly increased susceptibility to HSV infection 7. It is 
not clear how and where the virus exerts its TLR ligand stimulating effects. Likely possibilities 
include virus budding from infected epithelial cells, cell contents released by killed cells, or 
perhaps extracellular free virus. 
SK pathology is divided into two phases: non- clinical and clinical phase. In the non- clinical 
phase just after virus infection, innate immune cells such as DCs, natural killer (NK) cells, γδ-T 
cells, neutrophils and macrophages start playing their role in participating in viral clearance and 
the subsequent ocular inflammation. The cells secrete various effector molecules such as type I 
interferons, cytokines and chemokines (IL-17, IL-1β, IL-12, MIP-2, TNF-α, IFN-γ, IL-23)1. As a 
consequence, virus gets cleared from the eye but establishes latency in the TG. During the 
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clinical phase the cornea suffers an inflammatory reaction in which the adaptive immune 
response plays a vital role in causing immunopathology which mainly involves CD4+T cell 
compartment which can be of many subtypes in terms of function. Early on the major subtypes 
are Th1 cells along with FoxP3+ regulatory T cells9-10. In the later stages, Th17 cells become 
more evident, although these never exceed the Th1 cells11. By the time Th17 cells become 
prominent, CV is quite extensive and it is possible that some cytokines generated from Th17 
cells contribute directly or indirectly to the angiogenic process12.  
Treatment of Herpes virus infection 
Currently, patients with herpes infection undergoes treatment which involves a combination of 
anti-viral and anti-inflammatory drugs which include acyclovir, dexamethasone and prednisolone 
2,13. However, to control the chronic inflammatory reaction, long periods of anti-inflammatory 
drugs, particularly corticosteroids, are administered but these can have serious side effects such 
as risk of formation of cataract and glaucoma13. Additionally, corticosteroids may also promote 
HSV replication, which will worsen SK lesion severity 14.  
In consequence, we need to devise novel approaches to therapy in such a way that can either 
boost Tregs or shift the balance toward regulators to decrease SK immunopathology during the 
clinical phase of the disease or to target specifically effector T cells without affecting Tregs. Past 
studies from our laboratory suggest that depletion of Treg from the mice prior to infection results 
in more severe SK lesions10. It is important to highlight that many studies have advocated the 
differential susceptibility of Tregs to depletion and apoptosis inducing strategies. Therefore, in 
the SK model of disease, we have evaluated three different ways of reducing SK lesions and 
shifting the balance toward regulatory cells by targeting both T effectors and Treg by the use of 
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IL-28A mAB, a vitamin A metabolite, Retinoic acid and a monoclonal antibody CD28SA. 
Role of Interferons in virus infections 
Interferons are signaling proteins that are characterized by their ability to inhibit virus replication 
and resultant pathogenesis by triggering both innate and cell-mediated immune responses. The 
interferon system includes different types of interferons based on their functions which protects 
mammals against virus infections. Isaacs and Lindenmann in 1957 discovered this property of 
the large family of IFN proteins15 that induce the transcription of hundreds of IFN- stimulated 
genes (ISGs), whose protein products inhibit different stages of virus replication16. Since the 
inception of interferons, these have displayed ever increasing diversity and demonstrated activity 
far more refined than the original observation of the ability to ‘interfere’ with viral replication15.   
IFNs are key cytokines in the establishment of a multi-faceted antiviral response17. Each IFN 
family member works via engagement with their respective IFN receptor in producing an anti- 
viral response.  
There are three distinct types of IFNs, (type I, type II and type III), which differ based on their 
structure, receptor locations and biological functions. Although all types of IFNs stimulate innate 
and adaptive immune mechanisms that contribute to the clearance of viral infections, only type I 
and type III IFNs are directly produced in response to virus infections17. Type I, II, III IFNs are 
prominently distinguished by their distinct IFN receptor complexes18. Type I IFNs signal through 
the dimeric IFN-α/β receptor (IFNAR), consisting of IFNAR1 and IFNAR2 and these interferons 
comprise more than 10 subtypes of IFN-α, named IFN-α1, -α2, etc; IFN-β, -κ, -ω, -ε; and limitin. 
Type II IFNs bind to the tetrameric IFN-ϒ receptor (IFNGR), consisting of two subunits each of 
IFNGR1 and IFNGR2 and it involves only IFN-γ as subtype. Despite the early discovery of 
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interferon (IFN) in 1957, IFN lambdas were just recently identified and classified as a new 
group, type III IFNs19. The receptor to which IFN lambda binds is composed of the unique IFN-
λR1 chain also called IL-28AR and the IL-10R2 chain, which is shared with IL-10, IL-22 and 
IL-26 receptor complexes. There are 3 distinct proteins in human, called IFN-λ1, IFN-λ2 and 
IFN-λ3 which have been identified17. They are also designated as interleukin-29 (IL-29), IL-28A 
and IL-28B, respectively. IFN-λ1 (IL-29) is the main cytokine of this family produced in 
humans, but it is not expressed in mice and is considered as a pseudogene. In mice, IL-28 A/B 
play the major role 20. Although type III IFNs bind to a different specific receptor as compared to 
type I IFN, its downstream signaling is similar to that induced by type I IFNs. In humans, 
functional IFN-λ genes are clustered on chromosome 19, whereas, the type I IFN family genes 
are all encoded in a gene cluster on chromosome 9 21. The biological responses to the three IFN 
types overlap in some aspects, such as their ability to inhibit virus replication in infected cells. 
However, many effects of type I, type II, III signaling are distinct, especially in vivo.  These 
differences are based on two properties: the first defines the receptor expression of an IFN is cell 
type or tissue specific, not all IFNs and all receptors are produced by all cells. The second 
property relates to how the different IFN types activate different transcription factors to induce 
different groups of ISGs 22. For type I interferons, plasmacytoid dendritic cells (pDCs) are the 
dominant IFN-α producers in vivo after microbial infection, whereas IFN-ε is synthesized 
constitutively in the female reproductive tract 23-24. Whereas, the receptor for type I IFNs 
(IFNAR) is ubiquitously expressed, only cells of epithelial origin, as well as few others, such as 
hepatocytes, have the ability to respond to type III IFNs (IFN-λ). This is because these cell types 
express both IFNLR subunits 25,26. Type II IFNs (IFN-ϒ) are mainly synthesized by, natural 
killer cells, natural killer T cells, B cells and antigen presenting cells18. Such cell type- restricted 
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expression allows for localized, targeted IFN effects and this results in the prevention of 
uncontrolled systemic inflammation. Although IFN-λR1 is constitutively expressed by a broad 
range of cell lines and tissues, there are many cell types that do not express IFN-λ receptors, and, 
as a consequence, can not respond to treatment with this cytokine. For example, only type I IFNs 
but not type III IFNs can induce STAT activation in primary fibroblasts, human umbilical vein 
endothelial cells, and murine splenocytes. Peripheral blood mononuclear cells and bone marrow 
cells demonstrate only very weak activation in response to IFN-λ treatment and it appears that 
most leukocytes do not respond to IFN-λ even at high concentrations17.  
Biological activities of IFN-λ a signal transduction cascade which is very similar to that induced 
by type I IFNs (IFN-α or –β) so no wonder that type I and type III IFNs induce similar biological 
activities. Both types of IFN possess the intrinsic ability to induce antiviral activity in cells. IFN-
λ induced antiviral activity has been demonstrated against many different viruses, including 
encephalomyocarditis virus and vesicular stomatitis virus in several different cell types. IFN-λ 
exerts its effects in inhibiting hepatitis B virus (HBV) replication27. Consistent with their 
antiviral activity, the IFN-λs are usually coexpressed together with type I IFNs by virus infected 
cells17. Virtually any cell type can express IFN-λ following viral infection, and presumably 
infection by most viruses induces IFN-λ expression. For example, four distinct viruses (sindbis 
virus, Dengue virus, Vesicular stomatitis virus, and encephalomyocarditis virus) induce 
coexpression of IFN-λ1, -λ2 and –λ3 together with IFN-α and –β in several different human cell 
lines, including HeLa (cervical epithelial carcinoma), HT-29  (colorectal carcinoma and Huh7 
(hepatoma) 17. It is also known that infection of human epithelial cells by respiratory syncytial 
virus induces coexpression of type I and type III IFNs 28. In mice, infection with murine 
cytomegalovirus up-regulates  IFN-λ mRNA expression in-vivo. Other viruses, such as influenza 
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virus and sendai virus have also been shown to induce expression of IFN-λ in human monocyte-
derived dendritic cells (mDC). Moreover, it was shown that IFN-α amplifies induction of IFN-λ 
by influenza or sendai virus 28. Based on the current information, it appears that both the IFNα/β 
and the IFN-λ ligand –receptor systems are activated independently in response to viral 
infections. Inhibition of signaling through type I IFN receptors with neutralizing anti-IFNAR 
antibodies does not block signaling through type III IFN receptors. Similarly, inhibition of 
signaling through type III IFN receptors using neutralizing anti-IL-10R2 antibodies does not 
block signaling through type I IFN receptors. Signaling through IFNα/β receptors or IFN-λ 
receptors leads to the establishment of an antiviral state through the shared use of a common 
downstream signaling pathway and a common set of ISGs.  
Although type I IFNs are able to induce antiproliferative responses in many cell types, the 
antiproliferative activity of IFN-λ appears to be more limited 29. The antiproliferative activity of 
the IFN-λs has been demonstrated using several target cell types, including intestinal epithelial 
cells and the human glioblastoma cell line, LN319 29.  
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Importance of IFN-λ 
Viruses have evolved a variety of strategies by which they can inhibit the synthesis of interferons 
in the host body even after infection. Upon any viral infection, the host starts the synthesis of 
interferons once viral RNA is detected. Cellular sensors such as RIG-1 and TLRs activate the 
signaling pathways which induces the expression of antiviral genes which prevent the replication 
of viruses. Some viral proteins such as FLUAVNS1 and Ebola virus VP35, bind to viral RNA 
and hide it from detection by innate sensors 30,31 this in turn leads to interference with IRF-3 or 
IRF-7 phosphorylation, nuclear translocation or promoter binding32. Infection with HCV, using 
its protease NS3/4A, specifically cleaves and inactivates key signaling intermediates, such as the 
adapters MAVS and TRIF, inhibiting the RLR and TLR3 pathways33. IFN signaling can be 
targeted by soluble poxviral IFN decoy receptors by virus mediated degradation. They act to 
relocate STAT proteins or prevent ISGF3 formation which is the transcription factor required for 
the expression of interferon stimulating genes (ISGs) in infected cells32. Another way to stop the 
activation of the interferon system is to interfere with the functions of the ISG proteins 
themselves. FLUAV NS1 is a perfect example for this strategy as it directly binds and inhibits 
PKR34.  The antiviral defense activity of type III IFNs was highlightened by the recent discovery 
of a virus defense mechanism that directly targets type III IFNs 35. A secreted glycoprotein, 
known as Y136 produced by the yaba-like disease virus binds and inhibits signaling by both type 
I and type III IFNs. Y136 can also block IFN- mediated biological activities, including up- 
regulation of MHC class I antigen expression and induction of antiviral activity. The ability of 
Y136 to bind both type I and type III IFNs distinguishes this viral protein from the B18R protein 
which only blocks binding of type I IFNs.  
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IFN signaling 
As mentioned above, IFN-λ signaling occurs when IFN-λ proteins bind to a receptor complex 
consisting of IFN-λR1 chain and IL-10R2 chain. A step by step signaling process is depicted 
below:
           IFN-λ binds initially to the IFN-λR1 chain 
 
 
 
            which causes a conformational change that recruits the second receptor  
                          chain IL-10R2 to the complex 
 
                           this gives rise to a cascade of posttranslational modifications of  
                    intracellular signaling molecules, JAK-STAT signaling pathway initiates and results  
                   in activation of transcription factors such as IFN- stimulated gene factor 3 (ISGF3). 
 
 
This leads to formation of a binary complex 
This makes a ternary complex 
ISGF3 is made of 3 proteins, STAT1, STAT2 and IFN  
Regulatory factor-9 (IRF-9) Once assembled, ISGF3 then translocates to the 
nucleus where it binds to IFN-stimulated  response elements in the promoter 
regions of various ISGs such as OAS and MxA and induces anti-viral activity 
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Retinoic acid and HSV-1 Pathogenesis 
An organic chemical compound is called vitamin  which is needed by the body in limited 
amounts. When the organism can not synthesize the compound by itself, it has to be obtained 
through the diet. Currently, 13 vitamins have been recognized universally vitamin A, B1, B2, B3, 
B5, B6, B7, B9, B12, C, D, E and K. Every vitamin has its own role and function in the body and 
they are all essential for the normal growth and development of a multicellular organism. 
Vitamin deficiencies in the body can lead to the development of diseases which are mainly of 
two types: 
- Primary and secondary deficiencies: Primary deficiencies are those when the body lack 
adequate enough vitamin uptake because of diet. Whereas, secondary deficiencies occurs when 
there is a disorder which leads to prevention of the vitamin absorption. This disorder can be due 
to many factors. These include excessive alcohol consumption, smoking and intake of medicines 
which can interfere with vitamin uptake. These deficiencies can lead to diseases such as beriberi 
which is caused due to deficiency of thiamine. Niacin deficiency can cause pellagra and 
deficiencies of vitamin C and D can cause scurvy and rickets respectively. 
Among all these vitamins, vitamin A was found to have many interesting roles in embryogenesis 
36 and in immunity against various microbial and viral infections 37. The role of vitamin A was 
understood for first time in immunity in 1920s when Drs. Green and Mellaby observed that the 
dogs when fed a vitamin A deficit diet (VAD), succumb to an infection. Since then, a new role 
was given to vitamin A as “anti- infective vitamin” along with “growth producing vitamin”.38  In 
addition to this, studies have evidence to suggest that Vitamin A supplementation can improve 
vaccine efficacy39. In 1930s, Vitamin A was declared essential for the development of the 
immune system when VAD children were found to have atrophic thymi, spleens and lymphoid 
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tissues. Various cell components such as NK cells 40, T cells 41 and B cells 42 are involved in 
vitamin A’s impact on body. Diet is the only source from where retinoids (all vitamin A 
derivatives) can be obtained as retinoids are not synthesized de novo. Studies have shown that 
the liver is the main storage site of all the major proteins and enzymes involved in retinol storage 
and the uptake of vitamin A is in the intestine 43. Retinol is the major circulating retinoid in 
mammals and it binds to retinol- binding protein 4 (RBP4) and transthyretin (TTR) and is taken 
up by target tissues44. This uptake is facilitated by STRA6 (stimulated by retinoic acid gene 6) in 
various tissues.  
 
Retinoic acid synthesis from retinol 
It is a highly regulated process that involves several enzymes45 . Within the cell, there are two 
sequential steps which are required for the conversion of retinoic acid from retinol: It involves a 
process in which retinol gets oxidized to retinaldehyde (retinal) followed by the conversion of 
retinaldehyde to RA. It is a irreverisible conversion. Oxidation of retinol to retinaldehyde 
requires the enzymatic activity of several alcohol dehydrogenases (ADH -1, -4, -5) and oxidation 
of retinaldehyde to RA requires the activity of retinal dehydrogenases (RALDH). RA when 
released acts on different cells in a paracrine or autocrine manner. 
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                        Retinol (from diet) 
 
                    is converted to retinaldehyde (also called retinal) 
 
              retinaldehyde is irreversibly converted into all- trans retinoic acid (ATRA) 
Retinoic Acid is an active metabolite of vitamin A and as mentioned earlier it has various roles 
in embryonic development, apoptosis, reproduction and vision. Recent studies also revealed new 
roles of retinoic acid which is linked to various autoimmune diseases and inflammation46.  The 
Role of retinoic acid has also been studied as a means to improve cutaneous wound healing 47. 
Application of retinoic acid is also shown in ophthalmology in which retinol (vitamin A), 
ingested in food is absorbed by intestinal mucosal cells is bound to the serum retinol-binding 
protein and transported into target epithelial cells by a membrane receptor which is encoded by a 
gene stimulated by retinoic acid 6. Along with this, there is another enzyme known as lecithin 
retinol acytyltransferase which aids in uptake of retinol into cells 48. Once retinol reaches inside 
the cell, alcohol dehydrogenase, short chain dehydrogenases and retinol dehydrogenases 
performs the oxidation of retinol to retinaldehyde via a reversible reaction. Subsequently, 
additional enzymes play their role in converting retinaldehyde to retinoic acid by retinal 
dehydrogenases. The biosynthesis of retinoic acid inside the body is not difficult as most organs                     
can synthesize retinoic acid including corneal epithelial cells49. Ocular blood vessels transport 
vitamin A to the eye 50. Deficiency of vitamin A can seriously lead to vision impairment and  
By the action of cytosolic alcohol dehydrogenase 
(ADHs including ADH1, ADH5, and ADH7) and 
microsomal retinol dehydrogenase RDH  
By the action of retinaldehyde dehydrogenases 
(RALDH1, RALDH2 and RALDH3)  
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night blindness 51. 
 
Role of RA (retinoic acid) in CD4 T cell differentiation 
RA in Th17 differentiation 
For the differentiation of Th17 cells, IL6R, IRF4 and IL-23R are all required and RA is known to 
play a preventive action on all of these in the presence of TGF-β and hence, inhibits the 
generation of Th17 cells 52. 
Th1/Th2 differentiation in RA presence 
Past studies showed that Vitamin A deficit mice display excess Th1 and less Th2 generation by 
various mechanisms. Th2 differentiation was shown to be enhanced only in 9-cis-RA 
supplementation and not ATRA53. Iwata at al. 54 showed in the past studies that RA at > 1 nM 
directly suppressed Th1 but enhanced th2 differentiation. 
CD8+ T-cell differentiation 
Huang at al. in an oral immunization model of listeria monocytogens 55, showed that RA and 
TGF-β produced by MLN-DCs increased the expression of CD8αα on activated CD8αβ+T cells. 
This study promotes RA in introducing vaccination to induce Ag- sensitive CD8+ memory cells 
in the intestine for mucosal pathogen defense. For CD8+T cell survival during expansion, RA in 
the periphery is required 56. 
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RA and Treg induction and stability 
It has been shown by various studies that differentiation of naïve CD4+  T cells in the presence of 
RA and TGF-β can lead into stable FOXP3+ T cells both in vivo and in vitro 57. This RA 
dependant Treg differentiation involves the role of different types of APCs. It was shown that 
CD103+ and not CD103- MLN-DCs in the gut facilitates the conversion of naïve T cells into 
FOXP3+ Tregs 58. RA also plays an important role in the immune privilege of the eye . Retinal 
epithelial cells have the ability to produce both TGF-β and RA and with that effect even 
bystander CD4+T cells become FOXP3+ Treg. 
 Recent studies have shown that CD4+FOXP3+ regulatory T cells play essential roles in 
controlling autoimmune and inflammatory diseases 59. In the similar studies, during 
inflammation, another characteristic of these cells was revealed that these cells become plastic 
and lose their FOXP3 expression and gain T effector cell phenotype and worsen the disease 60. 
RA is shown to stabilize this plastic nature of Treg and prevent the induction of disease.  
From the past studies, it has been investigated that IL-6 exerts its effects in inducing DNMT1 (a 
DNA methyltransferase) mRNA expression in Tregs through the activation of STAT3. RA when 
introduced in a such a condition is hypothesized to have a role in downregulating the expression 
of STAT3 and with the effect, there is inhibition of IL-6 signaling which decreases the 
expression of DNMT1and hence leads to Treg stability. The mechanism of stabilization by RA is 
depicted in the following layout: 
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RA suppresses 
 
STAT3 activation 
          
                                               IL-6 to increase the expression of DNMT1 
 
                                           DNMT1 enhance demethylation levels of TSDR in Treg  
 
 
 
 
 
 
 
 
Which is required for  
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RA and Th1 suppression 
RA is known to induce the expression of SOCS3 which plays an important part in regulating the 
JAK/STAT pathway. SOCS3 when gets expressed, downregulates the signaling pathway of JAK 
kinases resulting in reduced expression of STAT1, STAT3 and IRF-1 proteins all of which are 
known to promote Th1 signaling. Hence, RA plays an important part in shutting down Th1 
pathway maturation and prevents many inflammatory diseases. This signaling event is described 
in the flowchart below:  
 
RA induces
 
 
SOCS3 expression which is a negative regulator of JAK/STAT pathway 
 
Induction of SOCS3 decreases STAT1, STAT3 and IRF-1 signals which are all required for Th1 
pathway maturation. 
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Another approach to lift the seesaw towards regulatory phenotype is the use of monoclonal 
superagonist antibody CD28 (CD28SA). These monoclonal antibodies function in a way that can 
induce polyclonal T – cell activation and specifically expand and activate Treg cells 61. It 
improves the function of Treg by making them more suppressive and potentiate their functions 
by increasing the activation markers on Treg 62. For a naïve T cell to get differentiated into 
further T cell subsets, it needs to get activated and for this purpose it requires two signals: 
The interaction of T cell receptor (TCR) molecules with the peptide /MHC complexes present on 
antigen presenting cells (APCs) provides the first signal. 
The second signal arises when there is engagement of a co-stimulatory receptor and still the most 
commonly known one is CD28. APCs are known to express the ligands (CD80 and CD86) for 
this receptor and this receptor ligand binding initiates the activation of T cells. There is a 
subclass of CD28 specific antibodies, as mentioned , the CD28SA which are capable of fully 
activating T cells without additional stimulation of the TCR61. These CD28SA leads to the 
formation of complexes formed by linearly arranged CD28 molecules and this leads to the 
aggregation of stimulatory signaling components such as phosphatidylinositol 3- kinase (PI3K) 
and growth factor receptor-bound protein 2 (Grb2) and all these signals leads to the strong 
activation signal.  
There are certain hypothesis as to why these CD28SA preferentially activates Treg cell 
population. 
- Treg cells are highly prone to apoptosis, but this can be prevented by the use of CD28SA 
as these antibodies induce antiapoptotic molecules such as BCL-XL. . 
- T conv cells synthesis IL-2 which is taken up by Treg cells and it contributes to their 
preferential expansion after CD28SA stimulation. 
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CD28SA (D665) and its action on Treg function 
CD28SA also performs a function in controlling the differentiation of naïve T cells into effector- 
T cell subpopulations and therefore, regulates the secretion of cytokines from Th1, Th2 and Th17 
cells 63. The downstream signals of CD28 stimulation can be divided into PI3K- dependent and 
independent pathways 63. The PI3K/AKT pathway contributes to T cell survival, activation and 
cytokine production63, 64. 
The first CD28SA, TGN1412, when underwent its first clinical phase1 trial, failed as it leashed a 
huge cytokine storm. The same CD28SA has now undergone successful phase 1 testing with a 
modified protocol and is now used as D665 CD28SA 65.
 
The outline of the mechanism of CD28SA is highlighted below 
 
 
 
 
 
 
 
  
 
  
CD28SA Injection 
 Enhances CD80 and CD86 ligand binding 
 to CD28R present on T cells 
Stimulates signaling pathway resulting in increase of Treg 
Promotes suppressive function of Treg  
by increasing activation markers on Treg 
which inhibits T- effector cell function and suppresses inflammation 
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Conclusions 
Even after understanding the complete pathogenesis cycle of HSV-1 and its relation with 
immune system, much is still left to be discovered. To understand pathological state of infection 
in each individual, both viral and host metabolism needs to be studied and linked together. This 
dissertation first describes the measure adopted to stop the replication of virus itself and studying 
the immune responses generated further.  
The second part of the thesis describes the role of a vitamin metabolite which can be easily 
generated from the diet and increasing its dose by providing it externally can have efficacious 
effects after infection. It has been studied in the experimental work done that it has the property 
of stabilizing the Treg cell population and at the same time, inhibiting T effector cell type and 
hence, shows as  a potential candidate to control SK lesions. The third part of the dissertation 
again focuses on Treg cell activation and function by the use of a monoclonal antibody, 
CD28SA. It also increases the ratio of treg to Th1 cell population. This treatment was 
administered once as prophylactic treatment and it significantly controlled SK lesion severity. 
In the end, this dissertation wrap up all the efforts that have been made to clinically investigate 
SK pathology and proposing different measures needed to control SK. 
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Appendix 
 
 
 
 
 
 
 
 
 
  
Figure 1.1. Principal events in HSV induced corneal SK pathogenesis: 
Following HSV infection of the cornea, replicating virus is detectable in the cornea until 
day 5-7 pi. Neutrophils infiltrate the cornea in a biphasic influx peaking first on day 2 pi. 
and then around day 11 pi. Development of new blood vessels from existing limbal 
vessels starts as early as day 1 pi. Influx of pathogenic CD4+ T lymphocytes occurs in the 
clinical phase around 7-9 days pi. 
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Chapter 2 
Role of type II Interferon Lambda (IL-28A) in Herpes Stromal 
Keratitis 
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Abstract 
Ocular infection with herpes simplex virus (HSV-1) can result in a chronic immune-
inflammatory lesion that is a significant cause of human blindness. A key to controlling Stromal 
Keratitis lesion severity is to suppress the activity of effector T cells and neutrophils that 
orchestrate the lesions and enhance the function of regulatory T cells. In this report, we focus on 
the early phase of immune response generated after viral infection which involves the function of 
innate cell type secretions such as Interferons. This study focuses on type III interferons which 
has been minimally investigated for effects on virus induced inflammatory lesions. 
Here we show that IL-28A (Interferon lambda type II) given early during infection has a 
pronounced antiviral effect and results in highly diminished inflammatory lesions. A virtue of 
Interferon lambda is that it also has its effect on some inflammatory cells involved in SK 
pathogenesis. Thus administering interferon lambda (IL-28A) during the early inflammatory 
responses when virus was substantially controlled also resulted in markedly reduced lesions. 
This inhibition was explained on the basis of anti-viral property of IL-28A which led to reduced 
Th1 cell number as well. To support our notion that IL-28A acts directly on neutrophils, 
inflammatory study has been done where IL-28A reduced the neutrophil number to a great 
extent. Thus, our results signify dual function of IL-28A which both comprises anti-viral and 
anti-inflammatory properties. 
 
. 
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Introduction 
Human blindness can be caused by ocular infection with Herpes Simplex Virus (HSV-1).1 This 
results from the immunopathology caused by the infiltration of Th1 cells and neutrophils which 
may result in chronic tissue- damaging response in the cornea.2-3 Animal models are being used 
to determine the nature of pathological events mediated by the infection. 
Several approaches have been shown to control the severity of HSK4 and the role of different 
immune cell types in controlling infection.5-6 Minimal attention has been given to interferons 
because of their limited contributions in immune cell biology. Past studies have shown that 
interferon gamma (type II interferons) knock out mice develop more severe HSK.7  Similarly 
IFN-alpha-treated (type I interferons) mice developed a normal CTL response to HSV-1 after 
corneal infection.8 Till now, no study has shown the effect of interferon lambda (type III 
interferons) in SK. Interferon lambda which is a type III interferon comprises IFN-λ1, IFN-λ2 
and IFN-λ3 (or IL-29, IL-28A and IL-28B respectively).9 Our main focus of the study is IFN-λ2 
(IL-28A) because of two factors. The first aspect deals with the anti-viral nature of type III 
interferons (Interferon lambda). Type III interferons have a role in inhibiting hepatitis B virus 
replication and also imposes a huge impact on hepatitis C virus replication.10 Past studies 
revealed that type I and type II interferons play a critical role in LCMV infection by reducing the 
viral loads in the initial stages of infection. However, in contrast type III interferons was unable 
to control LCMV infection.11 This suggests that although, type III interferons have the anti-viral 
properties, these may not be sufficient to control replication of all viruses. This led us to 
investigate if type III interferons would work for limiting viral replication in HSV-1 mediated 
immunopathology.  
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The second aspect of type III interferons focuses on anti-inflammatory effects. Thus, type III 
interferons (IL-28A) in a rheumatoid arthritis model has been shown to reduce inflammation by 
limiting the migration of neutrophils into the joint.12 Neutrophils play a critical role in HSV-1 
mediated pathology so that aroused interest in us to critically evaluate the role of IL-28A in SK 
model. 
Here we show that Interferon lambda (IL-28A) shows valuable approach to control  
immunopathological diseases caused by HSV-1in the eye. Interferon lambda acts by inhibiting 
the replication of virus and also, it promotes an immunological effect towards the reduction of all 
the SK mediators such as Th1 cells, neutrophils which needs to be put on halt. Additionally, to 
investigate the role of IL-28A in targeting neutrophil number, we designed an inflammatory 
model without viral infection and tested the function of IL-28A. The outcome was the reduced 
number of neutrophils. Taken together our results suggest that treatment with Pegylated IL-28A 
could be a promising therapy to treat HSK lesions. 
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Materials and Methods 
 
Mice 
Female 6-7 week-old C57BL/6 mice were purchased from Harlan Sprague Dawley Inc. 
(Indianapolis, IN).  The mice were taken care  in facilities at the University of Tennessee 
(Knoxville, TN) approved by the American Association of Laboratory Animal Care where food, 
bedding and instruments were autoclaved. All investigations followed guidelines of the 
institutional animal care and use committee. 
 
Virus 
HSV-1 strain RE Tumpey was propagated in Vero cell monolayers (American Type Culture 
Collection CCL81; Manassas, VA, USA). Infected Vero cells were harvested, titrated and stored 
in aliquots at -80°C until used. 
 
HSV-1 infection and clinical scoring 
C57BL/6 mice were given deep anesthesia and corneal infections were done by lightly scarifying 
corneas using a 27-gauge needle, and a 3-μL drop that contained 104 plaque-forming units of 
HSV-1 RE was put on one eye. These mice were monitored for the development of SK lesions.  
The SK lesion severity and angiogenesis in the eyes of mice were examined by slit-lamp 
biomicroscopy (Kowa Company, Nagoya, Japan). The scoring system was as follows: 0, normal 
cornea; +1, mild corneal haze; +2, moderate corneal opacity or scarring; +3, severe corneal 
opacity but iris visible; +4, opaque cornea and corneal ulcer; and +5, corneal rupture and 
necrotizing keratitis. The severity of angiogenesis was recorded as described previously. 
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According to this system, a grade of 4 for a given quadrant of the circle represents a centripetal 
growth of 1.5 mm toward the corneal center. The score of the four quadrants of the eye were then 
summed to derive the neovessel index (range, 0 to 16) for each eye at a given time point. 
 
IL-28A administration 
PEG-rIL-28m (IFNλ-2) (A Bristol-Myers Squibb Company) was formulated at a concentration 
of 12.93 mg/mL in PBS. It was administered intraperitoneally from day -1 to day15 Postinfection 
and in another set of experiments from day 3 postinfection to day 15 postinfection. The control 
group received equal volume of PBS. The dose of IL-28A was chosen based on our preliminary 
studies and previous reports. 
 
Viral Titers 
Eye swabs were taken from infected corneas which were treated with or without IL-28A using 
sterile swabs and were stored in -80 freezer. After obtaining all viral titers of different day points, 
titrations were performed by a standard plaque assay. Titers were calculated as log10 pfu/ml as 
per standard protocol. 
 
Quantification of mRNA Expression Levels by RT-PCR 
Total mRNA from corneal cells was isolated using the mirVana miRNA Isolation kit (Ambion). 
cDNA was made with 500ng of RNA (corneal samples). TaqMan gene expression assays for 
cytokines and chemokines were purchased from Applied Biosystems and quantified using the 
7500 Fast real-time PCR system (Applied Biosystems). The expression levels of different 
molecules were normalized to that of β- actin using the ΔCT method. 
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Neutrophil isolation 
C57BL/6 non- infected mice were treated with or without IL-28A and were challenged with 
Zymosan (1mg/ml) injected I.P. and after 4 hours, mice were terminated and 10 ml ice cold PBS 
was injected in peritoneum of mice and after a gentle massage on stomach, fluid was collected 
from the peritoneum. The cells were then centrifuged and neutrophils were then purified using 
Anti-Ly-6G Microbead kit (Miltenyi biotech). Neutrophils were further stained with pro-Il-1β 
and IL-17 PerCP antibodies. 
 
Flow Cytometric analysis 
On the day of termination, at day 15 p.i., corneas were excised, pooled groupwise, and digested 
with Liberase (Roche Diagnostics Corporation, Indianapolis, IN) for 30 mins at 37°C in a 
humidified atmosphere of 5% CO2. Following incubation, the corneas were disrupted by 
grinding with a syringe plunger on a cell strainer, and a single-cell suspension was made in 
complete RPMI 1640 medium. Cells were stimulated with phorbol 12-myristate 13- acetate plus 
ionomycin along with Golgi plug and incubated for 4 hours in CO2 incubator. Corneal single-
cell suspensions after stimulation were stained for different surface staining molecules for 
fluorescence-activated cell sorting (FACS). 
Draining lymph nodes (DLN) were obtained from mice terminated on day 15 postinfection, and 
single-cell suspensions were made as described for corneal samples and were stimulated and 
stained for cell surface markers followed by intracellular staining. Cells were kept on ice 
throughout the procedure and staining was done in U- bottom 96-well plates. The stained 
samples were acquired with a FACS LSR (BD Biosciences) and the data were analyzed using 
FlowJo software. 
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Statistics 
The statistical significance between the 2 groups treated with or without IL-28A was determined 
using unpaired, 1-tailed Student’s t test. P ≤ 0.001 (***), P ≤ 0.01 (**), P ≤ 0.05 (*) were 
considered significant, and results were expressed as means ± SEM and all experiments were 
repeated at least two times. For all statistical analysis, GraphPad Prism software (GraphPad 
Software, La Jolla, CA, USA) was used. 
 
Results 
IL-28A serves as an abatement in HSV-1 induced Immunopathology 
 To scrutinize the role of IL-28A in the pathogenesis of SK, mice were ocularly infected with 
HSV-1, and were treated everyday with pegylated recombinant mouse IL-28A intraperitoneally 
(IP) one day before infection. The SK lesions were then compared with the control group in 
which the mice were given PBS (IP). The results showed that mice treated with IL-28A showed 
markedly decrease lesion severity as compared to the exponential increase lesion severity in the 
control group. ( Figure 1A). As IL-28A has a prominent role as an antiviral agent, viral titers 
were also measured at day 1, 2 and 4. Ocular viral loads were present in control group but 
treatment with IL-28A inhibited viral loads as is seen on D1 P.I., there is a significant decrease 
of 2 log difference between IL-28A treated group of mice and control group and virus replication 
is inhibited on D2 and D4 P.I. (Figure 1B). 
 
Effect of IL-28A on cellular infiltration in the cornea after HSV-1 Infection 
 To evaluate the extent of neutrophil infiltration, pools of cornea were collected on D15 after 
treating one group of mice with IL-28A starting day 1 before infection. After collagen digestion, 
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the corneas were processed to quantify neutrophils and macrophages by FACS. The results 
indicate that the treatment with IL-28A reduces the influx of neutrophils and macrophages in the 
cornea at D15 P.I. (Figure  2A&E). Also, the number of CD4 T cells and CD45 T cells were 
reduced in the cornea. (Figure 2B&C). It also shows the ratio of reduced Th1 to Tregs in cornea. 
(Figure 2D).  
In additional experiments, ratios of cell types were compared in DLN in IL-28A treated and 
control infected animals. These cells were then stimulated for 4 hrs with PMA and ionomycin 
and CD4 T that were either IFN-γ producers or expressed the transcription factor FOXP3 were 
enumerated. Figure 3A &B shows the reduced influx of Th1 cells in the DLN on day 15 P.I. and 
also the ratio of Treg to Th1 cells is increased after the IL-28A treatment and figure 3C depicts 
the reduced number of the total number of CD4 T cells in DLN in IL-28A treated group as 
compared with the control group of animals.  
 
To demonstrate the effect of IL-28A after HSV-1 infection  
 To clinically observe the effect of IL-28A during the disease onset IL-28A treatment was begun 
on day 3 P.I., at this time the virus is usually present in the cornea and is actively replicating. We 
observed that treatment with IL-28A reduced the SK lesions as compared to the control group 
and also a day point scoring was done on D9, D12 and D14 (Figure 4A,B).  A similar kind of 
result was found in angiogenesis scores when measured on D14 P.I. (Figure 4C,D). Ocular viral 
loads in the cornea on D2, D4 and D6 P.I. were also observed and the results depicted lesser viral 
load at D4 and D6 P.I. after treatment with IL-28A. (Figure 4E).  
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Administration of IL-28A controls the influx of pathogenic neutrophils in the 
cornea 
Because the neutrophils and other immune cells enter the cornea after the viral clearance, which 
results in the destruction of the cornea, it is important to examine the effect of IL-28A in the later 
stages of the disease development. We observed that after treating the mice with IL-28A starting 
D3 P.I., the progression of HSK was decreased by less number of neutrophils and macrophages 
entering the cornea. (Figure 5A&B).  
Also, the effect was seen in DLN, as the number of Th1 cells were remarkably reduced in the 
DLN and the ratio of Treg to Th1 cells was increased. (Figure 6A&B). 
 
 IL-28A functions through heterodimeric receptor chain 
The signaling of Interferon lambda occurs through its receptor, which consists of two subunits: 
IL28R1 (also called as IFN-λR1, IL28Rα) and IL-10R2 subunit. To see the expression of these 
receptors after HSV-1 infection, we quantified the expression of these receptors by measuring 
their mRNA levels at different day points during the course of the disease progression. We 
observed that IL-28Rα is upregulated at D2 P.I. and is even expressed at D7 and D15 P.I. (Figure 
7A). Also the IL-10R2 is upregulated during the disease course and shows its maximum level of 
expression at D2 and D15 P.I. (Figure 7B). Studies have shown that LTB4R is known to recruit 
the neutrophils. To quantify the expression levels of LTB4R in our model, we did a day point 
kinetics and measured the mRNA levels of LTB4R in the HSV-1 pathogenesis cycle. We saw the 
expression of this receptor at D2 P.I. as well as D15 P.I. which revealed the highest expression. 
(Figure 7C). 
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 Neutrophil influx is restricted at the target site by IL-28A 
Previous studies showed that IL-28A downregulates LTB4R  and other neutrophil recruitment 
mediators and limits the access of neutrophils to the target site. To examine this effect of IL-28A 
in our model, we infected the mice with HSV-1 and treated the mice with IL-28A I.P. everyday 
and on D15 P.I., we pooled corneas to measure the mRNA levels of  LTB4R, MAC1, LFA1 and 
PSGL1. The results indicated that the treatment with IL-28A decreased the levels of LTB4R and 
other neutrophil mediators in the treated group and this hypothesize the lesser number of 
neutrophils in the cornea on D15 P.I. In addition, we also measured other pro-inflammatory 
cytokines in the cornea in the treated group and observed that mRNA levels of IL-6 and pro-IL-
1β was significantly reduced in IL-28A treated group as compared with control. (Figure 8). 
 
IL-28A controls neutrophil entry 
To further confirm the role of IL-28A in neutrophil inhibition, we used an inflammatory model, 
in which one group of mice were treated with IL-28A and others were given PBS as control 
group. After challenging the mice with zymosan (100μg) which induced inflammation, we 
observed that the mice pretreated with I.P. injection of IL-28A had lesser migration of 
neutrophils in the peritoneum as compared to the control group. This system was used to exclude 
the antiviral property of IL-28A and to see its effect in inflammatory state. IL-28A shows its 
anti- inflammatory property by reducing number of neutrophils in peritoneum and also limiting 
neutrophils with IL-1β production during inflammation. (Figure 9 A-C). 
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Discussion 
Ocular infection with herpes simplex virus (HSV-1) can result in a chronic immune-
inflammatory lesion that is a significant cause of human blindness. A key to controlling Stromal 
Keratitis lesion severity is to suppress the activity of effector T cells and neutrophils that 
orchestrate the lesions and enhance the function of regulatory T cells. In this report, we focus on 
the early phase of immune response generated after viral infection which involves the function of 
innate cell type secretions such as Interferons. This study focuses on type III interferons which 
has been minimally investigated for effects on virus induced inflammatory lesions. 
Here we show that IL-28A (Interferon lambda type II) given early during infection has a 
pronounced antiviral effect and results in highly diminished inflammatory lesions. A virtue of 
Interferon lambda is that it also has its effect on some inflammatory cells involved in SK 
pathogenesis. Thus, administering interferon lambda (IL-28A) during the early inflammatory 
responses when virus was substantially controlled also resulted in markedly reduced lesions. 
This inhibition was explained on the basis of anti-viral property of IL-28A which led to reduced 
Th1 cell number as well. To support our notion that IL-28A acts directly on neutrophils, 
inflammatory study has been done where IL-28A reduced the neutrophil number to a great 
extent. Thus, our results signify dual function of IL-28A which both comprises anti-viral and 
anti-inflammatory properties. 
Looking into the deep insights of HSK immunopathology, it is known that maintaining a balance 
which favors increase in Treg cell population and inhibiting T effector cell population in cornea 
can lead to lesser severity of SK lesions. Many known Anti-viral drugs and cortico-steroids have 
been in practice till now but with some inevitable side-effects after use.13 In this investigation, 
we propose a new approach of targeting cell population which contribute to SK pathology. A gift 
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from Bristol Meyer group lead us to a new direction of therapy which involved clearing the virus 
replication in cornea along with the fact which inhibited neutrophil population to a greater 
extent. SK is known to be orchestrated mainly by CD4 T cells primarily by Th1 cells and the 
neutrophils which comes during the adaptive phase of immune response.1-2 Pegylated 
recombinant mouse IL-28A (A gift from BMS) worked on three routes for clearing off 
immunopathology. It targets replication of the virus, inhibits neutrophil migration at the target 
site and along with that it restrains Th1 cell population also from fueling the lesion severity. 
Overall, our results shows that administering Il-28A as a prophylactic therapy in mice leads to 
less severity of SK lesions as it is known to be anti-viral and clears virus before it gets eradicated 
around day 6 P.I. as seen in control group and hence leads to reduced immunopathology. In 
another set of experiments, IL-28A was administered when virus was actively replicating in 
cornea on D3 P.I. and we observed that IL-28A clears  virus during that stage and depicts its 
anti-viral nature and along with that it works effectively during the onset of disease by causing 
reduced infiltration of neutrophils and Th1 cells in cornea. A recent study showed its another 
function as anti-inflammatory agent which can inhibit inflammatory cells from reaching the 
target site. This fact is highlightened when tried in a model which does not involve its anti-viral 
function. In another model to confirm its anti-inflammatory role, we designed an experiment in 
which mice were administered IL-28A and those mice were challenged with zymosan to induce 
inflammation and we observed that after inducing inflammation, neutrophils in peritoneum were 
reduced to a much greater extent than compared with controlled group. In-vivo, it does so by 
downregulating receptors which are known to recruit neutrophils during infection. We show here 
that it downregulates LTB4R1, PSGL1, MAC-1 and LFA-1 which leads to reduced neutrophils 
in cornea. This shows its anti-inflammatory role and in another study it was reported in HSV-2 
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infection that DCs constitute a key source of IFN-λ at epithelial surfaces in the female genital 
tract and that expression of type III IFN displays a higher level of dependence on the NF-κB 
pathway than expression of type I IFNs.11 
Interferons are developing a broad spectrum of therapy as past knowledge shows only anti-viral 
aspect of interferons but recently more work is being done in understanding the importance of 
interferons in adaptive immune response towards pathology. Interferons are classified into type I, 
II and III subtypes, based in part on the differential use of unique receptors through which they 
mediate signal transduction.  We focused on type III interferons particularly IL-28A which is 
sub- type of type III interferons. Interferon lambda receptors are found mainly in epithelial cells 
and it is one of the reasons that IL-28A can serve to be most effective in SK because HSV-1 
replicates in epithelial cells.9 In another report in mucosal infection with HSV-2, it has been 
observed that interferon lambda exerts its anti viral function by maintaining its antiviral state in 
epithelial cells14 which is also observed by us that IL-28A after HSV-1 infection led to a 
profound decrease in SK lesion severity. IL-28A functions by binding to its receptor which is 
composed of a heterodimeric chain of IFNLR1 and IL10RB. After HSV-1 infection, we saw an 
upregulation of receptor expression to which IL-28A can bind and initiate signaling effects. The 
protective role of IL-28A can be illustrated in two pathways, one is its anti-viral approach and 
another can be its anti-inflammatory effect which need further evaluation.  
In conclusion, in HSV-1 model, anti viral nature of  interferon lambda (IL-28A) has not been 
shown and emphasis on its new role as an anti- inflammatory agent has been put to light for the 
first time in HSV-1 induced immunopathology.   
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Figure 2.1. Prophylactic administration of IL-28A diminishes SK severity: 
C57BL/6 mice infected with HSV-1 (1X 104 PFU) were I.P. treated everyday with IL-28A or 
PBS one day before infection to D14 P.I. The disease progression was analyzed throughout 
time in a blinded manner. A, The progression of SK lesion severity was significantly reduced 
in a group of mice treated with IL-28A  as compared with control mice given PBS. B, To 
measure viral titers, eye swabs were taken from infected corneas from treated and control 
animals using sterile swabs on day1, day2 and d4 P.I. and titration was performed by standard 
plaque assay. The level of significance is determined by Student’s t-test (unpaired). *P 0.05, 
**P 0.01. Data represent mean ± SEM. These experiments are repeated two times. SSC, side 
scatter.  
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Figure 2.2. IL-28A treatment reduces cellular infiltration in corneas of HSV 
infected mice:  
C57BL/6 mice infected with HSV-1 (1X 104 PFU) were I.P. treated everyday with IL-28A or 
PBS on day1 before infection to D14 P.I.  A, Representative FACS plots and numbers of 
CD11b+ LY6G+ polymorphonuclear neutrophils gated on total CD45+ cells infiltrated in the 
corneas of control and IL-28A treated mice. B, Representative FACS plots and numbers of 
CD4+ T cells gated on total CD45+ cells infiltrated in the corneas of control and IL-28A 
treated mice are shown. C, Total number of CD45+ T cells and their representative FACS 
plots is shown. D, Histogram representing ratios of Treg to Th1 in the cornea at day 15 P.I. E, 
Histogram showing numbers of macrophages (CD45+ CD11b+ F4/80+) infiltrating the cornea 
at day 15 P.I. Data represent mean ± SEM. All experiments are repeated three times. *P ≤ 
0.05, **P ≤ 0.01. 
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Figure 2.3. Effect of IL-28A treatment on Treg and effector T cells in DLN 
of IL-28A treated animals:  
C57BL/6 mice infected with HSV-1 (1X 104 PFU) were I.P. treated everyday with IL-28A or 
PBS on day1 before infection to D14 P.I. A, It shows representative FACS plots and numbers 
of IFN-γ gated on total CD4 T cells. B, frequency and Cell numbers of FOXP3+ CD4T Cells 
and the cell ratios for total number of Tregs per Th1 cell. C, Representative FACS plots and 
numbers of CD4+ T cells in DLN in Il-28A treated animals. The level of significance is 
determined by Student’s t-test (unpaired). *P 0.05, **P 0.01. Data represent mean ± SEM. 
These experiments are repeated three times. SSC, side scatter 
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Figure 2.4. Therapeutic administration of IL-28A diminishes SK severity: 
C57BL/6 mice infected with HSV-1 (1X 104 PFU) were I.P. treated everyday with IL-28A or 
PBS on day3 to D14 P.I. The disease progression was analyzed throughout time in a blinded 
manner. A, Kinetics of SK severity is shown on D0, D8, D12 and D14 P.I. B, The progression 
of SK lesion severity was significantly reduced in a group of mice treated with IL-28A as 
compared with control mice given PBS. C, Kinetics of angiogenesis was measured on D0, 
D8, D12 and D14 P.I. D, The Progression of angiogenesis was significantly reduced in the 
group of mice treated with IL-28A as compared with control mice given PBS. E, To measure 
viral titers, eye swabs were taken from infected corneas from treated and control animals 
using sterile swabs on day2, day4 and d6 P.I. and titration was performed by standard plaque 
assay. The level of significance is determined by Student’s t-test (unpaired). *P 0.05, **P 
0.01. Data represent mean ± SEM. These experiments are repeated two times. SSC, side 
scatter.  
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Figure 2.5. IL-28A treatment reduces cellular infiltration in corneas of HSV 
infected mice Starting D3 P.I.:
C57BL/6 mice infected with HSV-1 (1X 104 PFU) were I.P. treated everyday with IL-28A or 
PBS on day3 P.I. to D14 P.I.  A, Representative FACS plots and reduced numbers of neutrophils 
in Il-28A treated animals. B, Representative FACS plots and reduced numbers of macrophages 
in Il-28A treated animals. The level of significance is determined by Student’s t-test (unpaired). 
*P 0.05, **P 0.01. Data represent mean ± SEM. These experiments are repeated three times.  
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Figure 2.6. IL-28A treatment reduces effector T cells in DLN of IL-28A 
treated animals of HSV infected mice starting D3 P.I.:
C57BL/6 mice infected with HSV-1 (1X 104 PFU) were I.P. treated everyday with IL-28A or 
PBS on day3 P.I. to D14 P.I. A, It shows representative FACS plots and numbers of IFN-γ 
gated on total CD4 T cells and total CD4 T cells. B, frequency and cell numbers of FOXP3+ 
CD4T Cells and cell ratios for total number of Tregs per Th1 cell. The level of significance is 
determined by Student’s t-test (unpaired). *P 0.05, **P 0.01. Data represent mean ± SEM. 
These experiments are repeated three times.  
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Figure 2.7. Interferon lambda constitutes two chains: 
 C57BL/6 mice infected with HSV-1 (1X 104 PFU). A, Corneas were collected on Day 2, 
7,11 & 15 and were processed and total RNA was extracted using MiRNA isolation kit and 
then q-RT- PCR was performed on the isolated RNA to measure the levels of IL-28R 
expression. B, q-RT- PCR was performed on the isolated RNA to measure the levels of IL-
10βR expression. C, mRNA levels of LTB4R in cornea is shown on D2, D7, D11 and D15 
P.I. The level of significance is determined by Student’s t-test (unpaired). *P 0.05, **P 0.01. 
Data represent mean ± SEM. These experiments are repeated three times.  
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Figure 2.8. Interferon lambda downregulates neutrophil recruitment 
mediators and also pro-inflammatory cytokine levels
C57BL/6 mice infected with HSV-1 (1X 104 PFU) and were treated with IL-28A. Corneas 
were collected on Day 2, 7 & 15 and were processed and total RNA was extracted using 
MiRNA isolation kit and then QRT- PCR was performed on the isolated RNA to measure the 
levels of LTB4R expression and other neutrophil recruitment mediators and pro-inflammatory 
cytokine levels were compared to the control group. The level of significance is determined 
by Student’s t-test (unpaired). *P 0.05, **P 0.01. Data represent mean ± SEM. These 
i d h i
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Figure 2.9. Treatment with IL-28A reduces influx of neutrophils in 
zymosan induced model: 
 C57BL/6 mice were treated with with IL-28A or PBS  A. Histogram showing no. of 
CD45+ T cells in peritoneum. B&C, Histogram showing reduced number of neutrophil 
population and IL-1β producing neutrophils. The level of significance is determined by 
Student’s t-test (unpaired). *P 0.05, **P 0.01. Data represent mean ± SEM. These 
experiments are repeated three times.
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Chapter 3 
Role of Retinoic acid in HSV-1 induced Immunopathology 
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Abstract 
Ocular infection with herpes simplex virus (HSV) can result in a chronic immune-inflammatory 
lesion that is a significant cause of human blindness. A key to controlling stromal keratitis lesion 
severity is to identify cellular and molecular events responsible for tissue damage and to 
counteract them. One potentially useful approach to achieve this is Retinoic Acid (R.A.). Here 
we show that R.A. therapy reduces the severity of SK by having inhibitory effects on the T 
effector subtypes responsible for orchestrating SK. RA also appeared to act to stabilize the 
function of regulatory T cell (Treg) which act to counteract inflammatory cell activity. The Treg 
stabilizing effect was demonstrated by in-vitro studies where RA was shown to restore Foxp3 
expression when exposed to pro- inflammatory conditions such as IL-12 and IL-6+TGF-β. In-
vivo studies revealed that RA exerted its stabilizing effects by downregulating IL-6R expression 
on Treg after HSV-1 infection and this helped to control the progression of SK. Since the therapy 
was effective when used both early and after the initiation of lesions, it may represent a valuable 
means of therapy when used alone or along with additional therapies.  
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Introduction 
Herpes Simplex Virus 1 (HSV-1) results in a chronic immunoinflamatory reaction in the cornea, 
which is primarily an immunopathological response to infection1-2. Mouse studies have revealed 
that the severity of SK lesions is influenced by the balance of CD4 T cell subsets responding to 
infection1-3. Severe responses occur if lesions are dominated by pro inflammatory Th1 and Th17 
cells but are modulated when regulatory T cells are expanded.4 Thus, potential approaches to 
therapy involve suppression of effector T cell subsets and expansion of the function of Treg(). A 
practical approach to achieve this objective could be to use the drug retinoic acid (RA). Past 
studies with retinoic acid revealed its involvement in the induction of Treg in gut-associated 
lymphoid tissue (GALT).5 An additional potential advantage of using RA is its reported effect on 
stabilizing Treg function in the presence of inflammatory cytokines.6 It is well known that Treg 
can lose their function in an inflammatory environment and this scenario has been observed in 
several models including studies with SK.6 Treg can be converted to Th17 cells in the presence 
of IL-6 and TGF-β in-vitro and also to Th1 cells in the provision of strong TCR stimulation.7 In-
vivo, in inflammatory models such as collagen induced arthritis presence of inflammatory 
cytokines such as IL-6, IL-1 and IL-23 caused Treg to lose their Foxp3 expression and to convert 
to proinflammatory Th1, Th17 or follicular helper cells and this explains their inability to 
suppress on-going inflammatory diseases.8 
We show that I.P. administration of RA starting prior to infection on D-2 and as a therapy 
starting on D5 P.I. led to a major reduction in lesion severity and markedly reduced 
inflammatory cell numbers in lesions. Additionally, in RA treated animals, neutrophils, the main 
mediators of tissue damage in SK, were reduced in number. By means of in-vitro studies, RA 
was shown to stabilize iTregs generated from naïve CD4+T cells. These iTregs when exposed to 
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different pro-inflammatory conditions, lose their Foxp3 expression. Our results showed that 
iTreg generated with RA showed reduced percentage of Foxp3 expression lost than iTreg 
generated without RA. The RA appeared to function by inhibition of IL-6R signaling and 
preserves Foxp3 expression leading to Treg stability. Using fate mapping mice which permitted 
the detection in-vivo and Treg plasticity. These mice allow the ability to differentiate between 
cells that currently express Foxp3 and cells that once expressed Foxp3 but now lack its 
expression which are referred to as ex- Tregs. Our results indicate that RA can serve as a brake 
to plasticity to some extent as the number of ex-Treg gets reduced in RA treatment group as 
compared to control. Thus, RA can prove to be an effective therapeutic agent which can 
minimize SK lesions given before or after the onset of the disease and hence control HSK. 
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Materials and Methods 
Mice 
Female 6-7 week-old C57BL/6 mice were purchased from Harlan Sprague Dawley Inc. 
(Indianapolis, IN).  The mice were taken care in facilities at the University of Tennessee 
(Knoxville, TN) approved by the American Association of Laboratory Animal Care where food, 
bedding and instruments were autoclaved. All investigations followed guidelines of the 
institutional animal care and use committee. 
 
Virus 
HSV-1 strain RE Tumpey was propagated in Vero cell monolayers (American Type Culture 
Collection CCL81; Manassas, VA, USA) 
Infected Vero cells were harvested, titrated and stored in aliquots at -80°C until used. 
 
HSV-1 infection and clinical scoring 
C57BL/6 mice were given deep anesthesia and corneal infections were done by lightly scarifying 
corneas using a 27-gauge needle, and a 3-μL drop that contained 104 plaque-forming units of 
HSV-1 RE was put on one eye. These mice were monitored for the development of SK lesions.  
The SK lesion severity and angiogenesis in the eyes of mice were examined by slit-lamp 
biomicroscopy (Kowa Company, Nagoya, Japan). The scoring system was as follows: 0, normal 
cornea; +1, mild corneal haze; +2, moderate corneal opacity or scarring; +3, severe corneal 
opacity but iris visible; +4, opaque cornea and corneal ulcer; and +5, corneal rupture and 
necrotizing keratitis. The severity of angiogenesis was recorded as described previously. 
According to this system, a grade of 4 for a given quadrant of the circle represents a centripetal 
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growth of 1.5 mm toward the corneal center. The score of the four quadrants of the eye were then 
summed to derive the neovessel index (range, 0 to 16) for each eye at a given time point. 
In addition, in some experiments, HSV footpad model was used. Mice were injected s.c. in each 
hind footpad with 4 × 105 PFU HSV-1 KOS in 30 μl PBS. Mice were sacrificed at day 5 
postinfection (p.i.), and the popliteal lymph nodes (PLN) were isolated for analysis. 
 
ATRA administration 
ATRA (Sigma aldrich) was administered at a concentration of 0.5 mg dissolved in 1000μl 
DMSO. Mice were injected with ATRA intraperitoneally from day -2 to day15 postinfection 
every other day and in another set of experiments from day 5 postinfection to day 15 
postinfection. The control group received equal volume of corn oil. The dose of ATRA was 
chosen based on our preliminary studies and previous reports. 
 
Histopathology 
Eyes from Control and ATRA treated mice were extirpated on day 15 pi and snap frozen in OCT 
compound (Miles, Elkart, IN). Six micron thick sections were cut, air dried in a desiccation box. 
Staining was performed with hematoxylin and eosin (Richard Allen Scientific, Kalamazoo, MI). 
 
Quantification of mRNA Expression Levels by RT-PCR 
Total mRNA from corneal cells was isolated using the mirVana miRNA Isolation kit (Ambion). 
cDNA was made with 500ng of RNA (corneal samples). TaqMan gene expression assays for 
cytokines and chemokines were purchased from Applied Biosystems and quantified using the 
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7500 Fast real-time PCR system (Applied Biosystems). The expression levels of different 
molecules were normalized to that of β- actin using the ΔCT method. 
 
In-vitro Treg differentiation 
Splenocytes isolated from DO11.10 RAG2 -/-  were used as a precursor population for the 
induction of Foxp3+ in CD4+ T cells as previously described. Briefly, 1×106 splenocytes after 
RBC lysis and several washings were cultured in 1ml RPMI media containing rIL-2 (100 U/ml) 
and TGFβ (1-5ng/ml) in the presence or absence of various concentrations of ATRA (0.5μm-
10μm) with plate bound anti-CD3/CD28 Ab (1 µg/ml) for 5 days at 37°C in a 5% CO2 
incubator. After 5 days, samples were characterized for Foxp3 intracellular staining (ebioscience 
staining kit) analyzed by flow cytometry. Treg were  cultured in 96-well round well bottom plate 
in the presence of IL-2 (100U/ml) or IL-12 (5ng/ml) or IL-6 (25ng/ml) +TGF-β (1ng/ml) for 3 
days followed by flow cytometry analysis of Live CD4+ Foxp3+ cells. 
 
Flow Cytometric analysis 
On the day of termination, at day 15 p.i., corneas were excised, pooled groupwise, and digested 
with Liberase (Roche Diagnostics Corporation, Indianapolis, IN) for 30 mins at 37°C in a 
humidified atmosphere of 5% CO2. Following incubation, the corneas were disrupted by 
grinding with a syringe plunger on a cell strainer, and a single-cell suspension was made in 
complete RPMI 1640 medium. Cells were stimulated with phorbol 12-myristate 13- acetate plus 
ionomycin along with Golgi plug and incubated for 4 hours in CO2 incubator. Corneal and DLN 
single-cell suspensions after stimulation were stained for different surface staining molecules for 
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fluorescence-activated cell sorting (FACS) analyses such as CD45 APCCY7, LY6G PERCP, 
F4/80 FITC, IFN-ϒ APC, FOXP3 PE, IL-17 PERCP, IL-6R PE, CD4 PERCP. 
Draining lymph nodes (DLN) were obtained from mice terminated on day 15 postinfection, and 
single-cell suspensions were made as described for corneal samples and were stimulated and 
stained for cell surface markers followed by intracellular staining. Cells were kept on ice 
throughout the procedure and staining was done in U- bottom 96-well plates. The stained 
samples were acquired with a FACS LSR (BD Biosciences) and the data were analyzed using 
FlowJo software. 
 
Statistics 
The statistical significance between the 2 groups treated with or without ATRA was determined 
using unpaired, 1-tailed Student’s t test. P ≤ 0.001 (***), P ≤ 0.01 (**), P ≤ 0.05 (*) were 
considered significant, and results were expressed as means ± SEM and all experiments were 
repeated at least two times. For all statistical analysis, GraphPad Prism software (GraphPad 
Software, La Jolla, CA, USA) was used. 
 
Results 
Retinoic acid diminishes HSV-1 induced immunopathology 
 To evaluate the role of RA signaling on the outcome of HSV-1 ocular infection, mice were 
given RA or DMSO (control) every other day with treatment starting on either on day -2 or day 
5pi. In the treatment begun on day -2, animals were examined at intervals to record the SK 
severity lesions and the treatment effects were first evident by day 9 followed by day 11 and day 
14 P.I. 
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(Figure 1A). RA administration resulted in significantly reduced SK lesion severity and corneal 
neovascularization compared to DMSO treated infected control mice. For example at day14pi, 
75% eyes showed lesion score of 3 or above in control DMSO group compared to 10% in RA 
treated (day -2) group (Figure 1B-D). This effect of reduced SK severity has been further 
supported by histological sections of corneas taken from mice treated with RA and compared to 
mice treated with DMSO terminated at day 15 P.I. (Figure 1E).  
     Further documentation of reduced inflammatory reaction in RA treated animals could also be 
shown by histological evaluation and by quantifying the extent of the inflammatory cellular 
events in subpools of corneas taken at day 15pi. The numbers of total leukocytes (CD45+ cells), 
neutrophils, macrophages and CD4+T in HSV-infected corneas were reduced significantly in 
mice treated with RA compared with control mice. Importantly, when the numbers of subsets of 
CD4+ T cells producing IFN-γ, were examined after stimulating with PMA/ionomycin, it was 
found that RA treatment markedly reduced Th1 populations in the infected corneas compared to 
control DMSO treated group.  (Figure 2A). 
   Parallel studies of a similar design were performed with T cells isolated from the draining 
lymph nodes (DLN) collected from the same animals used for corneal studies. The results shown 
in Figure 2B, demonstrate that along with reduced frequency of CD4+T cells, there was a 
significant decrease in Th1 cell population in DLN. Also, there was an increase in the ratio of 
total number of Treg per Th1 cells in RA treated mice as compared to mice treated with DMSO 
and the frequency of Treg is also increased. (Figure 2C). 
            In the experiments in which treatment was begun in the early clinical phase on day 5 after 
infection when replicating virus is mostly cleared from the HSV-1–infected corneas, SK scores 
were significantly diminished in the RA treated mice. The results revealed that 75% of the 
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animals in control group developed the disease score of 3 and above whereas, in the RA treated 
group, only 15% of the animals developed a disease score of 3 and above. (Figure 3A). In 
addition, histopathologic analysis showed decreased cellular infiltration and inflammation in the 
cornea in the RA treated group compared with the control DMSO group at day 15pi. (Figure 3B). 
Additionally, total leukocytes (CD45+ cells), neutrophils and macrophages were all also 
markedly diminished in RA treated group compared the control group at day 15pi (Figure 3C). 
As the outcome of SK lesion severity is dependant on the ratio of Treg to Th1, it was evident in 
Figure 3D that RA treatment shifts the balance of Th1 cells to Treg in DLN. 
Taken together, our results indicated that administration of RA during both preclinical 
and early clinical stages after HSV-1 infection diminished pathologic lesions and leukocyte 
infiltration. 
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RA treatment reduces Proinflammatory cytokines and chemokines after 
HSV-1 infection 
 To assess the effect of RA treatment on proinflammatory cytokine and chemokine production in 
SK, four corneas were pooled together and mRNA was prepared from corneal extracts on day 15 
after infection following treatment that was started on day -2 before infection. mRNA expression 
was quantified by quantitative real time PCR (Q-RTPCR). Proinflammatory cytokines  (IL-6, IL-
1β, IL-12) were reduced in the RA treated group compared to the control group. In addition, 
chemokines (KC, MMP9, CCL3) were also reduced in the RA treated group compared to control 
DMSO treated mice (Figure 4). These data indicate that the provision of RA to HSV-1–infected 
mice resulted in marked reduction of proinflammatory cytokines and chemokines. 
 
RA promotes differentiation and stability of Treg in vitro 
Past studies demonstrated that RA has in-vitro differentiation effects on CD4+T cells.(ref). To 
explore the differentiation effects of RA on Treg and T effectors (Th1 and Th17), experiments 
were performed in which naïve splenocytes from DO11.10 RAG2 KO animals (ova peptide-
specific and 98% naïve CD4+ T cells) were cultured in the presence of Treg differentiating 
conditions (IL-2 and TGF-β), as well as in the presence or absence of RA with a range of 
different doses (0.5 μM to 10 μM). The results showed that RA does not have a dose dependant 
effect on differentiation of Treg in-vitro. The expression of Foxp3 remains constant in the groups 
treated with or without RA (Figure 5A). Similarly, when naïve DO11.10 RAG KO splenocytes 
were cultured in the presence of  10um RA and Th1-differentiating conditions (IL-2 and anti-IL-
4 Ab), with or without RA, the outcome had no significant effect in Th1 differentiating 
conditions. (Figure 5B). However, on adding Th17 differentiating conditions (IL-6 and TGF-β) 
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in cultures of naïve DO11.10 RAG KO splenocytes, significantly decreased frequencies (about 
twofold decrease) of IL-17 in RA treated cultures was observed. (Figure 5C).  
After observing the differentiating effects of RA on subsets of CD4+T cells, the focus came to 
evaluate the effect of RA on Treg stability. For this purpose, iTregs were first generated as 
explained in figure 5A, and were then exposed to proinflammatory conditions that are known to 
destabilize Treg. The two iTreg populations, treated with or without RA were harvested and 
Foxp3 expression was determined following exposure for 3 days to IL-2 or IL-12 (Th1 
conditions) or to IL-6 and TGF-β (Th17 conditions). In agreement with previous reports, IL-2 
alone under nonstimulating conditions did not cause a change of Foxp3 expression. However, 
exposure to IL-6+TGF-β for 3 days resulted in loss of Foxp3 expression in around 25% of 
control iTreg cells as compared to 12% RA treated iTregs. Similarly, when iTreg were exposed 
to IL-12, Foxp3 expression was lost in 40% of control iTreg as compared to 25% of RA induced 
iTreg (Figure 6A). 
   In conclusion, results revealed that Treg induced in-vitro in the presence of RA were more 
stable in the presence of inflammatory cytokines (IL-12 or IL-6) than were Treg induced without 
RA.  
 
RA and Stability of Treg in-vivo 
Treg stability in HSV-1 model has already been described recently. RA is known to stabilize 
Treg and to elucidate this factor, experiments were done using fate mapping mice (FOXP3-GFP-
Cre: ROSA261s1-Td Tomato mice). These mice allow to differentiate between cells that 
currently express Foxp3 and cells that once expressed Foxp3 but now lack its expression, 
referred to as ex-Tregs. Fate Mapping mice have cells that can be separated, by flow cytometry 
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analysis into three main T cell populations that participate in SK lesions. Accordingly, Tregs that 
are CD4+GFP+Tomato+, ex-Tregs are CD4+Tomato+GFP- and effector CD4 T cells are 
CD4+Tomato-GFP-.  
To quantify the cytokine- producing abilities of these ex-Tregs, single-cell suspensions of Spleen 
were stimulated with PMA/ionomycin after foot-pad infection in these mice, followed by 
intracellular cytokine detection assay. As shown in figure 6B, IFN-γ produced from ex-Tregs 
was significantly reduced in spleen and also the number of these cells are reduced. Figure 6C 
shows the % and number of IFN-ϒ producing T effector cell population was also dramatically 
reduced as compared with the control group. 
These experiments generated results stating that RA stabilizes Treg by reducing the ex-Treg 
number in DLN and also reducing IFN-γ production from ex-Treg and T effector cell population.  
 
RA reduces IL-6R Expression and sustains the FOXP3 expression in-vivo 
It has been known that T cells express the IL-6R and therefore respond to proinflammatory 
cytokines. We sought to search the underlying mechanism of RA and its effect on Treg stability. 
CD126 is IL-6 receptor that is expressed on Treg and able to bind to IL-6 and mediate signals. 
Previous findings demonstrate that downregulation of IL-6R signal pathways may contribute to 
Treg stability. To evaluate the mechanism by which RA modulates effects in HSV-1 model, mice 
were ocularly infected with HSV-1 and RA was administered to one group of animals and other 
group was DMSO treated. On day 15 P.I. cells of DLNs and spleen were stained for IL-6R 
expression on Treg. The results revealed that RA treatment significantly reduced IL-6R 
expression on Treg in DLN and spleen which accounts for more Treg stability as IL-6 is known 
for the degradation of FOXP3 expression. (Figure 7).  
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Discussion 
Ocular infection with herpes simplex virus (HSV) can result in a chronic immune-inflammatory 
lesion that is a significant cause of human blindness.1 A key to controlling stromal keratitis 
lesion severity is to identify cellular and molecular events responsible for tissue damage and to 
counteract them. One potentially useful approach to achieve this is Retinoic Acid (R.A.). Here 
we show that R.A. therapy reduces the severity of SK by having inhibitory effects on the T 
effector subtypes responsible for orchestrating SK. RA also appeared to act to stabilize the 
function of regulatory T cell (Treg) which act to counteract inflammatory cell activity. The Treg 
stabilizing effect was demonstrated by in-vitro studies where RA was shown to restore Foxp3 
expression when exposed to pro- inflammatory conditions such as IL-12 and IL-6+TGF-β. In-
vivo studies revealed that RA exerted its stabilizing effects by downregulating IL-6R expression 
on Treg after HSV-1 infection and this helped to control the progression of SK. Since the therapy 
was effective when used both early and after the initiation of lesions, it may represent a valuable 
means of therapy when used alone or along with additional therapies.  
In order to control SK lesions, several approaches have been used9-10 but the use of RA was not 
previously evaluated. A novel way to design the same effect especially in stabilizing Treg cells 
in an inflammatory environment and regulating homeostasis has been depicted in this approach. 
In this study, the role of the vitamin A metabolite, ATRA was examined in inhibiting T effector 
cell population and regulating Foxp3 expression in an ongoing phase of viral infection with 
ocular HSV-1. Results indicate that prophylactic administration of ATRA inhibits interferon 
gamma production by Th1 cells in both corneas and draining lymph nodes which is a major 
mediator of SK lesions. Also, the outcome of the therapy was the increased ratio of Treg to Th1 
cells which probably can be due to the result shown that ATRA administration stabilizes Treg in 
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an inflammatory milieu. To further support this idea, in-vitro studies were done. Addition of pro-
inflammatory cytokines (IL-12 and IL-6) in the presence of ATRA displayed enhanced stability 
of the Foxp3 expression. In the mouse model for SK, the corneal damage is considered to result 
mainly from the actions by neutrophils and Th1 cells2,11 and the number of both cell types were 
reduced as a consequence of RA therapy. Also, a reduced influx of Th1 cells in cornea on D15 
P.I. along with the infiltration of neutrophils and macrophages was observed in cornea which 
results in preventing tissue damage. A similar response was found when RA was administered 
during the onset of the disease.  
Evidence from the past studies shows us that although Treg cells may be stable in normal 
conditions but in an inflammatory environment, these Treg cells may become plastic and some 
convert their regulatory phenotype into effector phenotype and hence become pathogenic.12-13  
ATRA pretreatment is known to prevent their conversion to pathogenic cells and by the help of 
Fate Mapping mice (FOXP3-GFP-Cre: ROSA261s1-Td Tomato mice) we have shown that 
ATRA administration leads to reduced number of ex-Treg cells and also the production of 
interferon gamma was reduced significantly from the effector Treg and ExTreg cell populations.   
Exactly how ATRA stabilizes Treg cells is not completely understood but one suggestion was its 
interference with the engagement of IL-6 to its receptor IL-6R8 . IL-6 being pro-inflammatory 
sets off a stage for inflammation which accounts for immunopathology.  
Our studies revealed that mice treated with ATRA show a decreased expression of CD126 (IL-
6R) in DLN which in turn protects Foxp3 expression as IL-6 is known to inhibit Foxp3 
expression and cause pathology. Additionally, our results showed that ATRA administration 
consistent with the decreased levels of IFN-γ, recruitment of inflammatory cells, such as 
neutrophils and macrophages was markedly decreased in the cornea. These results indicate that 
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ATRA may alleviate HSK by downregulating IL-6R and preventing Foxp3 degradation. Thus, 
overall we conclude that RA signaling in CD4+T cells is necessary for generation of immune 
response in-vivo. 
In summary, our results suggest a new therapy for SK patients undergoing chronic inflammatory 
damage which can be inhibited by the use of Retinoic Acid approach. From our results, RA 
therapy seems to hold a promise in the clinical prevention of SK lesions and results in the 
betterment of mankind. 
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Appendix 
Figure 3.1. Prophylactic administration of RA diminishes SK severity:  
C57BL/6 mice infected with HSV-1 (1X 104 PFU) were I.P. treated every other day with RA or 
DMSO two days before infection to D14 P.I. The disease progression was analyzed throughout 
time in a blinded manner. A, Kinetics of SK severity is shown measuring scores on D0, D9, D11 
and D14 P.I., B, The progression of SK lesion severity was significantly reduced in a group of 
mice treated with RA as compared with control mice given DMSO. C, Kinetics of  angiogenesis 
severity is shown measuring scores on D0, D9, D11 and D14 P.I. D, The Progression of 
angiogenesis was significantly reduced in the group of mice treated with RA  as compared with 
control mice given DMSO.  E, Eyes were processed for cryosections on day 15 P.I.  
Hematoxylin and eosin staining was carried out on 6-μm sections, and pictures were taken with 
different microscope augmentations at ×20 magnification. Data represent the mean results ± 
standard errors of the means (SEM). These experiments are repeated three times (n= 10 
mice/group). All data were analyzed with Student's t test and the Mann-Whitney U test. ***, P ≤ 
0.001. 
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Figure 3.2.  Prophylactic treatment of RA reduces the inflammatory cells in 
both cornea and DLN:
C57BL/6 mice infected with HSV-1 (1X 104 PFU) were I.P. treated every other day with RA or 
DMSO two days before infection to D14 P.I. A, representative FACS  plots and histogram 
showing frequencies and numbers of CD45+ CD11b+  LY6G + cells and CD45+ CD11b+  F4/80 + 
cells infiltrating the cornea at day 15 P.I B, Representative FACS plots and numbers of CD4+ T 
cells in DLN in RA treated animals.  C, It shows representative FACS plots and numbers of IFN-
γ and Foxp3 gated on total CD4 T cells and also Treg:Th1 ratio. Data are the combined results of 
at least 3 independent experiments and show mean values ± SEM (n = 3). The level of 
significance was determined by unpaired Student's t test. ****, P ≤ 0.0001; ***, P ≤ 0.001; 
**, P ≤ 0.01; *, P ≤ 0.05. 
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Figure 3.3. Therapeutic administration of RA diminishes SK severity:
C57BL/6 mice infected with HSV-1 (1X 104 PFU) were I.P. treated every other day with RA 
or DMSO from D5 P.I. to D14 P.I. The disease progression was analyzed throughout time in a 
blinded manner.  
A, The progression of SK lesion severity was significantly reduced in a group of mice treated 
with RA as compared with control mice given DMSO.  
B, Representative FACS  plots and histogram showing frequencies of CD45+ CD11b+  LY6G + 
cells and of CD45+ CD11b+  F4/80 + cells infiltrating the cornea at day 15 P.I  
C, Representative FACS  plots and histogram showing frequencies and numbers of  Th1 
(CD4+IFN-γ) and Treg (CD4+Foxp3+) and Treg:Th1 ratio at day 15 P.I. in DLN. Data are the 
combined results of at least 3 independent experiments and show mean values ± SEM (n = 3). 
The level of significance was determined by unpaired Student's t test. ****, P ≤ 0.0001; 
***, P ≤ 0.001; **, P ≤ 0.01; *, P ≤ 0.05. 
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Figure 3.4. Effects of RA treatment on cytokines and chemokines in the 
corneas of HSV-1 infected animals:  
C57BL/6 mice infected with HSV-1 (1X 104 PFU) were I.P. treated every other day with RA or 
DMSO two days before infection to D14 P.I. Mice were sacrificed at Day 15 P.I. and corneas 
were collected for qRT-PCR measurement of relative changes in mRNA expression of various 
cytokines (IL-6, IL-1β and IL-12 and chemokines (MMP9, CCL3 and KC) in pooled corneal 
samples. Samples consisted of four corneas, from control and RA treated animals. Data 
represent mean results ± SEM. These experiments are repeated two times. The level of 
significance is determined by unpaired Student's t test. ***, P ≤ 0.001; **, P ≤ 0.01; *, P ≤ 
0.05. 
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Figure 3.5. RA and its effect on Treg, Th1 and Th17 differentiating 
conditions:
Splenocytes from DO11.10 RAG2-/- mice were cultured (1 million cells) in the presence of 
1 μg/ml of anti-CD3/CD28 Abs under either Treg differentiating conditions, Th1 or Th17 
differentiating conditions. 
Treg differentiation was performed in the presence of 100 U/ml recombinant IL-2, 1 ng/ml 
TGF-β and  with various concentrations of RA (0.5μM to 10μM). After 5 days of culture, 
cells were analyzed for the expression of CD4 and Foxp3. A, representative FACS plots and 
histogram showing Foxp3 expression in cells cultured under Treg- differentiating conditions 
in the presence or absence of RA. B, representative FACS plots and histogram showing the 
expression of IFN-γ in cells cultured under Th1-differentiating conditions (5 ng/ml IL-12 
and 10μg/ml anti- IL-4) in the presence or absence of RA. C, Representative FACS plots 
and histogram showing the expression of IL-17 in cells cultured under 25 ng/ml IL-6 and 
1ng/ml TGF-β in the presence or absence of RA. Experiments were repeated at least three 
times. The level of significance was determined by unpaired student’s  t test. Error bars 
represent mean results ± SEM. ****, P ≤ 0.0001; ***, P ≤ 0.001; **, P ≤ 0.01; *, P ≤ 0.05.
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Figure 3.6. RA promotes stability of Treg in-vitro:  
Splenocytes from DO11.10 RAG2-/- mice were cultured in the presence of 1 μg/ml of 
anti-CD3/CD28 Abs, 100 U/ml recombinant IL-2 and 5 ng/ml TGF-β in the presence and 
absence of RA 10μM for 5 days. After 5 days of culture, they were exposed to 100U/ml 
IL-2, 5ng/ml IL-12 or 25ng/ml IL-6 and 1ng/ml TGF-β for another 3 days. Cells were 
measured for live CD4+Foxp3+ cells before and after exposure. Histogram represents the 
frequency of Foxp3 lost by cells of control and RA- induced Treg exposed to different 
conditions.  
RA promotes stability of Treg in-vivo   
FM mice were infected with 4 × 105 PFU HSV-1 KOS and single cell suspensions were 
made from DLN and spleens of these mice and intracellular staining was done to quantify 
ex-Tregs by stimulating them with PMA/ionomycin.  
B, Represenatative FACS plots and histograms showing number of ex-Tregs producing 
IFN-γ.  
C, Represenatative FACS plots and histograms showing number of t- effectors producing 
IFN-γ. Experiments were repeated at least three times. The level of significance was 
determined by unpaired Student's t test. Error bars represent mean results ± SEM. 
****, P ≤ 0.0001; ***, P ≤ 0.001; **, P ≤ 0.01; *, P ≤ 0.05.
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Figure 3.7. Treg maintain their phenotype and function via downregulation 
of IL-6R expression:
C57BL/6 mice infected with HSV-1 (1X 104 PFU) were I.P. treated every other day with RA 
or DMSO two days before infection to D14 P.I. The disease progression was analyzed 
throughout time in a blinded manner. Single cell suspensions were made from DLN and 
spleens and were stained for CD126 (IL-6R) on Tregs and the expression was determined by 
FACS. A, Histograms showing frequency of IL-6R, the MFI frequency and also the number 
of IL-6R expressing Tregs is shown in spleen. B, Histograms showing frequency of IL-6R, 
the MFI frequency and also the number of IL-6R expressing Tregs in DLN. Experiments were 
repeated at least three times. The level of significance was determined by unpaired 
Student's t test. Error bars represent mean results ± SEM. ****, P ≤ 0.0001; ***, P ≤ 0.001; 
**, P ≤ 0.01; *, P ≤ 0.05. 
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Abstract 
Ocular infection with herpes simplex virus (HSV) can result in a chronic immune-inflammatory 
lesion that is a significant cause of human blindness. A key to controlling stromal keratitis (SK) 
lesion severity is to identify cellular and molecular events responsible for tissue damage. 
Regulatory T cells (Tregs) are known for preventing autoimmune diseases like systemic lupus 
erythematosus (SLE), multiple sclerosis (MS), Type 1 diabetes (T1D), rheumatoid arthritis (RA) 
and Inflammatory bowel disease (IBD). Furthermore, Tregs play an important role in reducing 
the severity of SK lesions by inhibiting the immune responses which cause immunopathology. 
Interestingly, there is a class of “superagonistic” CD28 specific mAb which are able to 
preferentially expand and activate Tregs. Previous studies have shown that treating mice with a 
CD28 superagonistic antibody (CD28SA) ameliorated the acute signs of arthritis and completely 
prevented the development of chronic destructive arthritis in a mouse model. In the present 
study, we report that a single injection with CD28SA mAb given on day -2 as a prophylactic 
therapy, reduced the severity of SK lesions. We found increased ratio of Treg in mice treated 
with CD28SA with enhanced activity of Tregs, as CD28SA increased activation markers and 
enhanced proliferation of Treg. Thus, our studies demonstrate the usefulness of CD28SA as a 
therapeutic agent to control virus induced immunopathology. 
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Introduction 
Recent evidence have shown that 80% or more of the adult human population is affected by 
herpes simplex virus (HSV).1 The pathogenesis of SK is known to involve the activity of T 
lymphocytes at large.2-3 At the effector stages, Th1 cells are known to play pathogenic roles in 
the disease course and Treg are the powerful candidates for preventing or reducing the 
immunopathology caused by HSV-1.1 Primary infection with herpes simplex virus can lead to 
conjunctivitis that can cause inflammation of the eyelids.4 In order to reduce immunopathology, 
one way can be achieved by shifting the balance towards  Tregs and making them dominant over 
the other proinflammatory T cell population.5-6 Lesions can become severe if not treated 
effectively or if  Tregs are depleted prior to infection or if they are suppressed during the 
ongoing infection state.7,5 Tregs are known to control autoimmune diseases like systemic lupus 
erythematosus (SLE), multiple sclerosis (MS), Type 1 diabetes (T1D) rheumatoid arthritis (RA) 
and IBD (Inflammatory bowel disease) like diseases.8 
The aim of this study was to evaluate the role of CD28 superagonists (CD28SA) which are 
monoclonal antibodies that induce polyclonal T- cell activation and preferentially expand and 
activate Treg.9 Studies have shown that such mAB are effective expanders and activators of 
Tregs in rats9,10 and mice.11-12  CD28SA act on both T effectors and Tregs , in-vitro and in-vivo 
and the IL-2 produced by Tconvs in response to CD28SA stimulation is immediately utilized by 
Tregs, which leads to their functional activation.12 The CD28 superagonist-expanded and 
activated Treg cells are then capable of suppressing autoreactive pathogenic T cells (Tpath), 
thereby preventing the onset or if already established autoimmune response. 10 Previous studies 
showed treating mice with a CD28 superagonistic antibody (CD28SA) ameliorated the acute 
signs of arthritis and completely prevented the development of chronic destructive arthritis. 13 
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Here, we show that a single mAb injection with CD28SA(D665) on D-2 as a prophylactic 
therapy appeared to specifically enhance the Treg cell population and maintains not only their 
phenotype but also their regulatory functions and thus effectively reduced SK lesions. The 
overall focus of the study will be to show that administration of CD28SA can effectively reduce 
SK pathogenesis. 
 
Materials and Methods 
Mice 
Female 6-7 week-old C57BL/6 mice were purchased from Harlan Sprague Dawley Inc. 
(Indianapolis, IN).  The mice were taken care  in facilities at the University of Tennessee 
(Knoxville, TN) approved by the American Association of Laboratory Animal Care where food, 
bedding and instruments were autoclaved. All investigations followed guidelines of the 
institutional animal care and use committee. 
 
Virus 
HSV-1 strain RE Tumpey was propagated in Vero cell monolayers (American Type Culture 
Collection CCL81; Manassas, VA, USA) 
Infected Vero cells were harvested, titrated and stored in aliquots at -80°C until used. 
 
HSV-1 infection and clinical scoring 
C57BL/6 mice were given deep anesthesia and corneal infections were done by lightly scarifying 
corneas using a 27-gauge needle, and a 3-μL drop that contained 104 plaque-forming units of 
HSV-1 RE was put on one eye. These mice were monitored for the development of SK lesions.  
 87 
The SK lesion severity and angiogenesis in the eyes of mice were examined by slit-lamp 
biomicroscopy (Kowa Company, Nagoya, Japan). The scoring system was as follows: 0, normal 
cornea; +1, mild corneal haze; +2, moderate corneal opacity or scarring; +3, severe corneal 
opacity but iris visible; +4, opaque cornea and corneal ulcer; and +5, corneal rupture and 
necrotizing keratitis. The severity of angiogenesis was recorded as described previously. 
According to this system, a grade of 4 for a given quadrant of the circle represents a centripetal 
growth of 1.5 mm toward the corneal center. The score of the four quadrants of the eye were then 
summed to derive the neovessel index (range, 0 to 16) for each eye at a given time point. 
 
D665 administration 
D665 (a kind gift from university of Wurzburg) was administered at a concentration of 
100ug/mouse of antibody in 100ul of PBS on D-2 prior to infection. Mice were injected with 
single administration of D665 intraperitoneally on day -2 and in another set of experiments on 
day 4 postinfection. The control group received equal volume of sterile PBS. The dose of D665 
was chosen based on our preliminary studies and previous reports. 
 
Histopathology 
Eyes from Control and D665 treated mice were extirpated on day 15 pi and snap frozen in OCT 
compound (Miles, Elkart, IN). Six micron thick sections were cut, air dried in a desiccation box. 
Staining was performed with hematoxylin and eosin (Richard Allen Scientific, Kalamazoo, MI). 
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Quantification of mRNA Expression Levels by RT-PCR 
Total mRNA from corneal cells was isolated using the mirVana miRNA Isolation kit (Ambion). 
cDNA was made with 500ng of RNA (corneal samples). TaqMan gene expression assays for 
cytokines and chemokines were purchased from Applied Biosystems and quantified using the 
7500 Fast real-time PCR system (Applied Biosystems). The expression levels of different 
molecules were normalized to that of β- actin using the ΔCT method. 
 
Flow Cytometric analysis 
On the day of termination, at day 15 p.i., corneas were excised, pooled groupwise, and digested 
with Liberase (Roche Diagnostics Corporation, Indianapolis, IN) for 30 mins at 37°C in a 
humidified atmosphere of 5% CO2. Following incubation, the corneas were disrupted by 
grinding with a syringe plunger on a cell strainer, and a single-cell suspension was made in 
complete RPMI 1640 medium. Cells were stimulated with phorbol 12-myristate 13- acetate plus 
ionomycin along with Golgi plug and incubated for 4 hours in CO2 incubator. Corneal single-
cell suspensions after stimulation were stained for different surface staining molecules for 
fluorescence-activated cell sorting (FACS) analyses. 
Draining lymph nodes (DLN) were obtained from mice terminated on day 15 postinfection, and 
single-cell suspensions were made as described for corneal samples and were stimulated and 
stained for cell surface markers followed by intracellular staining. Cells were kept on ice 
throughout the procedure and staining was done in U- bottom 96-well plates. The stained 
samples were acquired with a FACS LSR (BD Biosciences) and the data were analyzed using 
FlowJo software. 
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Statistics 
The statistical significance between the 2 groups treated with or without ATRA was determined 
using unpaired, 1-tailed Student’s t test. P ≤ 0.001 (***), P ≤ 0.01 (**), P ≤ 0.05 (*) were 
considered significant, and results were expressed as means ± SEM and all experiments were 
repeated at least two times. For all statistical analysis, GraphPad Prism software (GraphPad 
Software, La Jolla, CA, USA) was used. 
 
Results 
Treatment with D665 Reduces the Severity of HSV-1 Induced Corneal 
Immunopathology 
To investigate the role of CD28SA (D665) in the pathogenesis of SK, mice were ocularly 
infected with HSV-1, and were treated with a single administration of D665 intraperitoneally 
(IP) two days before infection. Animals were examined at intervals to record the severity of SK 
lesions, as well as the extent of corneal neovascularization. The SK lesions were then compared 
with the control group in which the mice were given PBS (IP). The results showed that mice 
treated with D665 showed markedly decrease lesion severity as compared to the exponential 
increase lesion severity in the control group. (Figure 1) 
 
D665 administration reduces the cellular infiltration in cornea 
To evaluate the extent of D665 on cellular infiltration in the cornea after HSV-1 infection, four 
pools of cornea were collected on D15 and after collagen digestion, the corneas were processed 
to quantify IFNγ+ CD4+ T cells and FOXP3+CD4+T cells. The FACS analysis reveal that after 
the administration of D665 in mice, these mice show reduced influx of Th1 cell infiltration. 
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(Figure 2A). Also, the Treg ratio in the cornea was increased and it also shows the ratio of 
reduced Th1 to Tregs in cornea. (Figure 2B).  
Parallel studies of a similar design were performed with T cells isolated from the draining 
Lymph nodes (DLN) and the ratios of cell types were compared in DLN in D665 treated and 
control infected animals. These cells were then stimulated for 4 hrs with PMA and ionomycin 
and CD4 T that were either IFN-γ producers or expressed the transcription factor FOXP3 were 
enumerated. Figure 3A&B shows the reduced influx of Th1 cells in the DLN on day 15 P.I. and 
also the ratio of Treg to Th1 cells is increased after D665 treatment.  
 
Administration of D665 controls the influx of pathogenic neutrophils in the 
cornea 
Because the neutrophils and other immune cells enter the cornea after the viral clearance, which 
results in the destruction of the cornea, it is important to examine the effect of D665 in the course 
of the disease development. Four corneas were pooled together and were collected on D15 and 
after collagenase digestion, the corneas were processed to quantify CD11b+Ly6G+ cells. We 
observed that after treating the mice with D665, the progression of SK was decreased by reduced 
number of neutrophils entering the cornea. (Figure 4).  
 
D665 increased Treg Proliferation and activation markers 
To determine Treg population and suppressive capabilities, mice were treated with D665 and 
single cell suspensions from DLN were made and stained with KI67, proliferation marker for 
Treg. Results reveal that D665-treated group shows more proliferation of Treg as compared with 
control group of animals. (Figure 5A). Comparisons were also made between Treg in control and 
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D665 treated animals for activation markers and the results showed a modest increased 
expression of activation markers which includes CTLA4, CXCR3, CD103, and CD44 on Foxp3+ 
CD4 T cells. (Figure 5B). 
 
Increasing Foxp3+ Tregs in secondary lymphoid tissues during the 
progression of clinical disease follows a trend in the reduction of the SK 
severity 
Next, we ascertained whether increasing Foxp3+ Tregs during the onset of the clinical disease 
period modulated the progression of corneal opacity. One group of HSV-1 infected mice 
received D665 treatment on day 4 postinfection whereas the control group of infected mice was 
given i.p. injection of PBS. On day 15 postinfection, mice were euthanized and the numbers of 
Foxp3+ Tregs and Th1 cells in DLNs from both groups were quantified by flow cytometry. Our 
results showed a significant increase in the ratio of Foxp3+ Tregs in DLNs but along with that 
there was a significant increase in the number of Th1 cells too which explains the reason towards 
a decreased trend in the SK lesions when given D665 treatment therapeutically. (Figure 6&7). 
 
Discussion 
Ocular infection with herpes simplex virus (HSV) can result in a chronic immune-inflammatory 
lesion that is a significant cause of human blindness.14-15 A key to controlling stromal keratitis 
(SK) lesion severity is to identify cellular and molecular events responsible for tissue damage.16 
Regulatory T cells (Tregs) are known for preventing autoimmune diseases like systemic lupus 
erythematosus (SLE), multiple sclerosis (MS), Type 1 diabetes (T1D), rheumatoid arthritis (RA) 
and Inflammatory bowel disease (IBD).17,18 Furthermore, Tregs play an important role in 
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reducing the severity of SK lesions by inhibiting the immune responses which cause 
immunopathology.19,20 Interestingly, there is a class of “superagonistic” CD28 specific mAb 
which are able to preferentially expand and activate Tregs. Previous studies have shown that 
treating mice with a CD28 superagonistic antibody (CD28SA) ameliorated the acute signs of 
arthritis and completely prevented the development of chronic destructive arthritis in a mouse 
model.13  In the present study, we report that a single injection with CD28SA mAb given on day 
-2 as a prophylactic therapy, reduced the severity of SK lesions. We found increased ratio of 
Treg in mice treated with CD28SA with enhanced activity of Tregs, as CD28SA increased 
activation markers and enhanced proliferation of Treg. Thus, our studies demonstrate the 
usefulness of CD28SA as a therapeutic agent to control virus induced immunopathology. 
Our results clearly showed markedly reduced SK lesions in response to HSV-1 infection in D665 
treated animals. In our model, on D15 P.I., there is a huge influx of neutrophils and Th1 cells 
which cause inflammation and results in tissue damage. CD28SA is a monoclonal antibody 
which has a role in the expansion and activation of Tregs. 
In a healthy immune system, the balance between Treg and T conventional is controlled by 
mechanisms which mutually control survival and proliferation of both types. One cardinal 
feature of CD28SA is that it preferentially expands Treg cell population while inhibiting T 
effector cells.21 It controls the proliferation, survival and also differentiation of Tregs and at the 
same time, it inhibits pro inflammatory cytokines produced by T-effector cells such as interferon 
gamma, IL-17, IL-1β and various other chemokine and cytokines which results in 
inflammation.12 
Exact mechanism of the study has not been identified. There are certain hypothesis regarding the 
function of CD28SA which might contribute to its role. First, CD28SA stimulation is able to 
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trigger downstream pathways, one of which might be NFκB pathway. Secondly, CD28SA 
stimulation is very effective in inducing IL-2 production by T effector cells, which is used by 
Treg cells as these themselves do not produce IL-2 so Tregs use IL-2 produced by T effector 
cells and hence, generates their survival rates and induces proliferation. Last factor which 
contributes to its mechanism might be the induction of apoptosis. Treg cells are highly 
susceptible to apoptosis. The efficacy of CD28 signaling is shown to prevent apoptosis by 
inducing anti- apoptotic genes such as Bcl-2 by various different studies.13-21 Our study 
highlights the importance of using CD28SA as a therapy as it effectively diminishes SK lesion 
severity when given the treatment as prophylactic administration.  
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Figure 4.1.  Prophylactic treatment with D665 reduces SK lesions:  
C57BL/6 mice infected with HSV-1 (1X 104 PFU) were I.P. treated only once with D665 at 
day -2 before infection. The disease progression was analyzed throughout time in a blinded 
manner. The progression of SK lesion severity was significantly reduced in a group of mice 
treated CD28SA as compared with control mice.  
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Figure 4.2. D665 treatment reduces effector T cells in cornea of treated 
animals of HSV infected mice:   
C57BL/6 mice infected with HSV-1 (1X 104 PFU) were I.P. treated once on day -2 with 
CD28SA. A, It shows representative plots of reduced frequencies and numbers of Th1 
cells. B, representative plots of cell ratio of FOXP3+ CD4T Cells and also cell ratios for 
total number of  Tregs per Th1 cell.  
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Figure 4.3. Effect of D665 treatment on Treg and effector T cells in 
DLN:  
C57BL/6 mice infected with HSV-1 (1X 104 PFU) were I.P. treated with D665 once at 
day -2 before infection. A, representative FACS plots showing reduced numbers of IFN-γ 
gated on total CD4 T cells. B, Cell ratio of FOXP3+ CD4T cells and the ratio for total 
number of  Tregs per Th1 cell.   
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Figure 4.4. Effect of D665 treatment on infiltration of neutrophils in 
cornea:  
C57BL/6 mice infected with HSV-1 (1X 104 PFU) were I.P. treated with D665 once at day-
2 before infection. A, representative FACS plots showing reduced numbers of 
Ly6G+CD11b+gated on total CD45 T cells.
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Figure 4.5. D665 treatment increases the proliferation of Tregs in DLN 
on D15 P.I. and activation markers:  
C57BL/6 mice infected with HSV-1 (1X 104 PFU) were I.P. treated with CD28SA once 
day -2 before infection. A, Histogram representing increased proliferation of Tregs in 
DLN. B, Proportions of Treg in DLN expressing CTLA4+, CXCR3+ CD103+ and 
CD44+.Cells were gated on CD4+FOXP3+ cells. 
 
 102 
 
 
 
 
 
 
 
 
 
  
control CD28SA D4 P.I.
0
1
2
3
4
5
SK
 le
si
on
 s
co
re
s 
D1
4 
P.
I.
herapeutic treatment with D665 reduces SK lesions: 
 C57BL/6 mice infected with HSV-1 (1X 104 PFU) were I.P. treated only once with D665 at 
day -2 before infection. The disease progression was analyzed throughout time in a blinded 
manner. The progression of SK lesion severity followed a trend towards reduced SK 
severity in a group of mice treated CD28SA as compared with control mice.  
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Figure 4.7. Effect of therapeutic D665 treatment on Treg and effector T 
cells in DLN:  
C57BL/6 mice infected with HSV-1 (1X 104 PFU) were I.P. treated with D665 once at 
day 4 P.I. A, representative FACS plots showing reduced numbers of IFN-γ gated on total 
CD4 T cells. B, Cell ratio of FOXP3+ CD4T cells and the ratio for total number of  Tregs 
per Th1 cell.   
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Chapter 5 
Conclusions and future perspectives 
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Stromal Keratitis develops when there is an immunoinflammatory response caused by HSV-1 
infection of the cornea. In rare circumstances, virus can damage the eyes (herpetic stromal 
keratitis) or brain (herpes simplex encephalitis). To resolve SK, current use of anti-viral drugs 
and corticosteroids are unsatisfactory, thus HSK remains the leading cause of infectious 
blindness in the western world. The pathogenesis of SK involves mainly the role of T cells so 
approaches that can either inhibit or eliminate T effector subtypes or boost Treg responses would 
be encouraged. The work described in this dissertation sheds light on some of these measures by 
using therapies that specifically target T effector population and hence, generating effective ways 
to reduce SK lesions. 
In our first approach the focus was on inhibition of viral replication using  novel form of 
interferon, Interferon lambda (IL-28A) that has received limited evaluation against HSV. The 
virtue of IL-28A is that it was reported to have additional anti-inflammatory responses, a major 
advantage to control SK. In our studies, after virus infection, we found the upregulation of the 
receptor (IL-28R) for  IL-28A. On administering IL-28A by I.P. route in mice, we observed 
reduced SK lesions as compared with control group. Also, on D3 P.I., there was reduced severity 
of SK lesions. IL-28A when administered on D5 P.I., did not reduce SK lesions and we plan to 
extend our observations in understanding as to why IL-28A is not able to reduce lesion severity 
when given on D5 P.I. To the best of our knowledge, we understand that Interferon lambda is 
beneficial during the early stages of infection but as the infection develops, interferon lambda is 
not sufficient to control the spread of viral replication. We are interested to perform some 
additional experiments looking into the combination therapy with type 1 interferons and 
examining results after treatment of mice with both type 1 and type 3 interferons on D5 P.I. One 
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of the mechanisms of IL-28A is its anti-viral activity which is very well known, our future 
perspectives intend to look into its anti-inflammatory activity as well. 
The second approach involves the regulation of Treg responses after viral infection with the use 
of Retinoic acid. RA is known to hold relevance in different pathways leading to the generation 
of a hemeostatic immune response in various studies. It is usually obtained from diet but in our 
experimental studies, we observed that providing RA externally modulated immune response to 
a regulatory phenotype and preventing SK lesion severity. It works well both as prophylactic and 
therapeutic administration. Our experiment results revealed that although RA stabilizes Treg cell 
responses, it does not increase Treg cell numbers. Further attempts will be made in order to use 
Butyrate as a combination with RA which might increase Treg numbers as well. We chose 
butyrate as a partner for RA as butyrate is also known to have regulatory effects by maintaining a 
reservoir of Treg cell pool. We also intend to do some more stabilizing studies using TSDR 
methylation studies in our further plans.  
Our third and final approach involves the study of monoclonal antibody (CD28SA) in evaluating 
its response in Treg metabolism. We have shown that after the administration of CD28SA, 
CD28SA acts on Treg by increasing the proliferation of Treg and also improving the function of 
Treg by enhancing the activation markers on Treg. Along with the effects on Treg cell 
population, CD28SA also inhibits the effector T cell subtype, Th1 cells and hence, contributing 
towards SK prevention. Additional experiments of our study will involve ways as to how this 
might function in order to achieve the regulatory phenotype. We plan to design experiments on 
measuring IL-2 production by Teff cells which is consumed by Treg cells and in turn making 
them more dominant by increasing their functions. Additional experiments will involve the 
stabilizing studies of Treg by using in-vitro and in-vivo approaches. 
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